RayKnowChina Research Map
Shortlist

Cancer

Stomach cancer

胃癌

Tumours or cancer of the stomach.

Definition adapted from MeSH (US National Library of Medicine)

hospitals in mainland China
211

with a paper from 2016–2025 or a registered study

cities
67

where those hospitals are

open trials in China
408

ClinicalTrials.gov, 8 Nov 2026

Mainland China accounts for 49% of the world's English-language research papers on stomach cancer, 2021–2025 (38% in 2016–2020), and 33% of the world's registered trials on it have a site in China.

Research activity in public records, not a rating of care and not medical advice. How the numbers are made

211 hospitals in 67 cities

Order: papers led on stomach cancer, 2021–2025, then A–Z. Research activity, not a rating of care.

A hospital is listed when it led at least 11 papers or 1 trial on stomach cancer, or was a site in 8 or more trials. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first. Hospitals not listed may also treat it. Definitions

A square is a city. Its size and number are hospitals listed for this disease, not the amount of research. Choose one to show that city in the hospital list and the trial list.

Cities with the most listed hospitals

  1. Shanghai17
  2. Beijing15
  3. Guangzhou15
  4. Hangzhou9
  5. Nanjing8
  6. Jinan7
  7. Shenzhen7
  8. Chongqing6
  9. Chengdu5
  10. Fuzhou5

Each opens stomach cancer in that city. 57 more cities are in the menu below.

  1. 223 papers led
  2. Jiangsu Province Hospital

    江苏省人民医院(南医大一附院)Nanjing

    199 papers led
  3. Fujian Medical University Union Hospital

    福建医科大学附属协和医院Fuzhou

    168 papers led
  4. 168 papers led
  5. Chinese PLA General Hospital

    中国人民解放军总医院Beijing

    140 papers led
  6. Zhongshan Hospital, Fudan University

    复旦大学附属中山医院Shanghai

    134 papers led
  7. 131 papers led
  8. Nanfang Hospital

    南方医科大学南方医院Guangzhou

    128 papers led
  9. 113 papers led
  10. First Hospital of China Medical University

    中国医科大学附属第一医院Shenyang

    109 papers led
  11. 108 papers led
    No open trial led
  12. 107 papers led
  13. 106 papers led
  14. 105 papers led
  15. 105 papers led
  16. 104 papers led
  17. 103 papers led
  18. 98 papers led
    No open trial led
  19. Ruijin Hospital

    上海交通大学医学院附属瑞金医院Shanghai

    96 papers led
  20. 90 papers led
  21. 88 papers led
  22. 84 papers led
    No open trial led
  23. 80 papers led
  24. 78 papers led
  25. Union Hospital

    华中科技大学同济医学院附属协和医院Wuhan

    78 papers led
  26. 76 papers led
    No open trial led
  27. Henan Cancer Hospital

    河南省肿瘤医院Zhengzhou

    76 papers led
  28. 74 papers led
  29. 69 papers led
  30. Harbin Medical University Cancer Hospital

    哈尔滨医科大学附属肿瘤医院Harbin

    66 papers led
    No open trial led
  31. First Affiliated Hospital, Zhejiang University

    浙江大学医学院附属第一医院Hangzhou

    65 papers led
  32. Renji Hospital

    上海交通大学医学院附属仁济医院Shanghai

    65 papers led
  33. Xijing Hospital

    空军军医大学西京医院Xi'an

    62 papers led
  34. 60 papers led
    No open trial led
  35. 59 papers led
  36. 57 papers led
    No open trial led
  37. 55 papers led
  38. 55 papers led
  39. 54 papers led
    No open trial led
  40. 52 papers led
    No open trial led
  41. 52 papers led
    No open trial led
  42. 46 papers led
    No open trial led
  43. 45 papers led
  44. 45 papers led
    No open trial led
  45. 45 papers led
  46. Tongji Hospital

    华中科技大学同济医学院附属同济医院WuhanInternational Medical Department

    45 papers led
  47. Sir Run Run Shaw Hospital

    浙江大学医学院附属邵逸夫医院Hangzhou

    44 papers led
    No open trial led
  48. 41 papers led
  49. 40 papers led
  50. 39 papers led
    No open trial led
  51. 38 papers led
  52. Fujian Cancer Hospital

    福建省肿瘤医院Fuzhou

    38 papers led
  53. 38 papers led
    No open trial led
  54. 37 papers led
    No open trial led
  55. 35 papers led
    No open trial led
  56. 35 papers led
    No open trial led
  57. Xiangya Hospital

    中南大学湘雅医院Changsha

    35 papers led
    No open trial led
  58. 33 papers led
    No open trial led
  59. 33 papers led
  60. 33 papers led
    No open trial led
  61. 32 papers led
    No open trial led
  62. Second Xiangya Hospital

    中南大学湘雅二医院Changsha

    32 papers led
    No open trial led
  63. Central Hospital Affiliated to Shandong First Medical University

    山东第一医科大学附属中心医院(济南市中心医院)Jinan

    31 papers led
    No open trial led
  64. Changhai Hospital

    海军军医大学第一附属医院(长海医院)Shanghai

    31 papers led
  65. 31 papers led
  66. 31 papers led
  67. 30 papers led
    No open trial led
  68. 30 papers led
    No open trial led
  69. Zhongshan Hospital, Xiamen University

    厦门大学附属中山医院Xiamen

    30 papers led
    No open trial led
  70. 29 papers led
  71. 29 papers led
  72. First Affiliated Hospital of Zhejiang Chinese Medical University

    浙江中医药大学附属第一医院(浙江省中医院)Hangzhou

    29 papers led
    No open trial led
  73. Hainan General Hospital / Hainan Medical University hospitals

    海南医学院附属医院/海南省人民医院Haikou

    29 papers led
    No open trial led
  74. 29 papers led
  75. 28 papers led
    No open trial led
  76. 27 papers led
  77. 27 papers led
    No open trial led
  78. Shanghai General Hospital

    上海市第一人民医院Shanghai

    27 papers led
  79. Shengjing Hospital of China Medical University

    中国医科大学附属盛京医院Shenyang

    27 papers led
    No open trial led
  80. First Affiliated Hospital of Shandong First Medical University

    山东第一医科大学第一附属医院(山东省千佛山医院)Jinan

    26 papers led
    No open trial led
  81. Jiangsu Cancer Hospital

    江苏省肿瘤医院Nanjing

    26 papers led
    No open trial led
  82. 26 papers led
  83. 26 papers led
  84. 26 papers led
    No open trial led
  85. 25 papers led
    No open trial led
  86. Hunan Cancer Hospital

    湖南省肿瘤医院Changsha

    25 papers led
  87. 25 papers led
  88. 24 papers led
    No open trial led
  89. 24 papers led
    No open trial led
  90. 24 papers led
    No open trial led
  91. Southwest Hospital, Army Medical University

    陆军军医大学第一附属医院(西南医院)Chongqing

    24 papers led
  92. Xinhua Hospital

    上海交通大学医学院附属新华医院Shanghai

    24 papers led
    No open trial led
  93. 23 papers led
    No open trial led
  94. 23 papers led
    No open trial led
  95. China-Japan Union Hospital, Jilin University

    吉林大学白求恩第三医院(中日联谊医院)Changchun

    22 papers led
    No open trial led
  96. First Affiliated Hospital of USTC

    中国科学技术大学附属第一医院(安徽省立医院)Hefei

    22 papers led
    No open trial led
  97. 22 papers led
  98. 22 papers led
  99. 21 papers led
    No open trial led
  100. 21 papers led
    No open trial led
  101. 21 papers led
    No open trial led
  102. 21 papers led
    No open trial led
  103. 21 papers led
  104. 21 papers led
  105. 21 papers led
    No open trial led
  106. Shanghai Sixth People's Hospital

    上海市第六人民医院Shanghai

    21 papers led
    No open trial led
  107. Shanghai Tenth People's Hospital

    上海市第十人民医院Shanghai

    21 papers led
    No open trial led
  108. 21 papers led
  109. Zhongda Hospital, Southeast University

    东南大学附属中大医院Nanjing

    21 papers led
  110. 20 papers led
    No open trial led
  111. Jinling Hospital

    东部战区总医院(金陵医院)Nanjing

    20 papers led
  112. 20 papers led
    No open trial led
  113. Second Hospital of Dalian Medical University

    大连医科大学附属第二医院Dalian

    20 papers led
    No open trial led
  114. Tongde Hospital

    浙江省立同德医院Hangzhou

    20 papers led
    No open trial led
  115. 19 papers led
    No open trial led
  116. 19 papers led
    No open trial led
  117. 19 papers led
    No open trial led
  118. 19 papers led
    No open trial led
  119. 18 papers led
    No open trial led
  120. Ningbo Medical Center Lihuili Hospital

    宁波市医疗中心李惠利医院Ningbo

    18 papers led
    No open trial led
  121. Xinqiao Hospital, Army Medical University

    陆军军医大学第二附属医院(新桥医院)Chongqing

    18 papers led
    No open trial led
  122. 17 papers led
    No open trial led
  123. 17 papers led
    No open trial led
  124. 17 papers led
    No open trial led
  125. Changzheng Hospital

    海军军医大学第二附属医院(长征医院)Shanghai

    17 papers led
  126. 17 papers led
    No open trial led
  127. Taizhou Hospital, Wenzhou Medical University

    温州医科大学附属台州医院Taizhou

    17 papers led
    No open trial led
  128. Third Xiangya Hospital

    中南大学湘雅三医院Changsha

    17 papers led
    No open trial led
  129. Tongji Hospital

    同济大学附属同济医院Shanghai

    17 papers led
    No open trial led
  130. 16 papers led
    No open trial led
  131. 16 papers led
    No open trial led
  132. 16 papers led
    No open trial led
  133. 16 papers led
    No open trial led
  134. Suzhou Ninth People's Hospital

    苏州市第九人民医院Suzhou

    16 papers led
    No open trial led
  135. Zibo Central Hospital

    淄博市中心医院Zibo

    16 papers led
    No open trial led
  136. 15 papers led
    No open trial led
  137. 15 papers led
    No open trial led
  138. Beijing Tongren Hospital

    首都医科大学附属北京同仁医院Beijing

    15 papers led
    No open trial led
  139. Chongqing University Cancer Hospital

    重庆大学附属肿瘤医院Chongqing

    15 papers led
    No open trial led
  140. 15 papers led
    No open trial led
  141. 14 papers led
    No open trial led
  142. 14 papers led
    No open trial led
  143. 14 papers led
    No open trial led
  144. 14 papers led
    No open trial led
  145. 14 papers led
    No open trial led
  146. 14 papers led
    No open trial led
  147. Tangdu Hospital

    空军军医大学唐都医院Xi'an

    14 papers led
  148. 14 papers led
    No open trial led
  149. 13 papers led
    No open trial led
  150. Huai'an First People's Hospital

    淮安市第一人民医院Huai'an

    13 papers led
    No open trial led
  151. Longhua Hospital

    上海中医药大学附属龙华医院Shanghai

    13 papers led
    No open trial led
  152. Sichuan Cancer Hospital

    四川省肿瘤医院Chengdu

    13 papers led
    No open trial led
  153. 12 papers led
    No open trial led
  154. 12 papers led
    No open trial led
  155. 12 papers led
    No open trial led
  156. 12 papers led
    No open trial led
  157. Guangxi Medical University Cancer Hospital

    广西医科大学附属肿瘤医院Nanning

    12 papers led
    No open trial led
  158. 12 papers led
    No open trial led
  159. 12 papers led
    No open trial led
  160. 12 papers led
    No open trial led
  161. 11 papers led
    No open trial led
  162. 11 papers led
    No open trial led
  163. 11 papers led
    No open trial led
  164. 11 papers led
    No open trial led
  165. Hangzhou First People's Hospital

    杭州市第一人民医院Hangzhou

    11 papers led
    No open trial led
  166. Sun Yat-sen Memorial Hospital

    中山大学孙逸仙纪念医院Guangzhou

    11 papers led
  167. 11 papers led
    No open trial led
  168. Anyang Tumor Hospital

    安阳市肿瘤医院Anyang

    10 papers led
    No open trial led
  169. 10 papers led
  170. Zhujiang Hospital

    南方医科大学珠江医院Guangzhou

    10 papers led
    No open trial led
  171. 9 papers led
  172. Guang'anmen Hospital

    中国中医科学院广安门医院Beijing

    9 papers led
  173. Minhang Hospital

    上海市闵行区中心医院Shanghai

    9 papers led
    No open trial led
  174. 8 papers led
    No open trial led
  175. Hubei Cancer Hospital

    湖北省肿瘤医院Wuhan

    8 papers led
    No open trial led
  176. 8 papers led
    No open trial led
  177. Shanxi Cancer Hospital

    山西省肿瘤医院Taiyuan

    8 papers led
    No open trial led
  178. Wenzhou Central Hospital

    温州市中心医院Wenzhou

    8 papers led
  179. Yunnan Cancer Hospital

    云南省肿瘤医院Kunming

    8 papers led
  180. Xuzhou Central Hospital

    徐州市中心医院Xuzhou

    7 papers led
    No open trial led
  181. Eastern Hepatobiliary Surgery Hospital

    海军军医大学第三附属医院(东方肝胆外科医院)Shanghai

    6 papers led
    No open trial led
  182. 6 papers led
    No open trial led
  183. 5 papers led
    No open trial led
  184. 5 papers led
    No open trial led
  185. Xuanwu Hospital

    首都医科大学宣武医院Beijing

    5 papers led
    No open trial led
  186. 4 papers led
    No open trial led
  187. 4 papers led
    No open trial led
  188. 4 papers led
  189. 4 papers led
    No open trial led
  190. Huadong Hospital, Fudan University

    复旦大学附属华东医院Shanghai

    4 papers led
  191. Jiangxi Cancer Hospital

    江西省肿瘤医院Nanchang

    4 papers led
    No open trial led
  192. 4 papers led
  193. 4 papers led
  194. Cancer Hospital CAMS – Shenzhen

    中国医学科学院肿瘤医院深圳医院Shenzhen

    3 papers led
  195. 3 papers led
    No open trial led
  196. 3 papers led
    No open trial led
  197. 2 papers led
    No open trial led
  198. 2 papers led
  199. Linyi Cancer Hospital

    临沂市肿瘤医院Linyi

    1 paper led
    No open trial led
  200. Linyi People's Hospital

    临沂市人民医院Linyi

    1 paper led
    No open trial led
  201. 1 paper led
  202. 1 paper led
    No open trial led
  203. Yishui Central Hospital

    临沂市中心医院Linyi

    1 paper led
    No open trial led
  204. 0 papers led
    No open trial led
  205. Fuda Cancer Hospital

    广州复大肿瘤医院Guangzhou

    0 papers led
    No open trial led
  206. Harbin Medical University Hospital

    哈尔滨医科大学附属医院(试验登记未写明哪一家)Harbin

    0 papers led
  207. Jilin Cancer Hospital

    吉林省肿瘤医院Changchun

    0 papers led
    No open trial led
  208. 0 papers led
    No open trial led
  209. PLA Navy Anqing Hospital

    中国人民解放军海军安庆医院Anqing

    0 papers led
    No open trial led
  210. Xuzhou Second People's Hospital

    徐州市第二人民医院Xuzhou

    0 papers led
    No open trial led
  211. Yixing People's Hospital

    宜兴市人民医院Wuxi

    0 papers led
    No open trial led

By university or health system 59

Hospitals carrying a university’s name, added together, plus papers that name only the university. Same order as above.

  1. Nanjing Medical University

    南京医科大学Nanjing

    378 papers led
    6 hospitals
  2. Peking University Health Science Center

    北京大学医学部Beijing

    323 papers led
    6 hospitals
  3. Fujian Medical University

    福建医科大学Fuzhou

    316 papers led
    6 hospitals
  4. Sun Yat-sen University

    中山大学Guangzhou

    283 papers led
    6 hospitals
  5. Fudan University

    复旦大学Shanghai

    281 papers led
    6 hospitals
  6. Shanghai Jiao Tong University School of Medicine

    上海交通大学医学院Shanghai

    276 papers led
    6 hospitals
  7. Zhengzhou University

    郑州大学Zhengzhou

    255 papers led
    6 hospitals
  8. Peking Union Medical College / Chinese Academy of Medical Sciences

    北京协和医学院/中国医学科学院Beijing

    210 papers led
    6 hospitals
  9. Zhejiang University School of Medicine

    浙江大学医学院Hangzhou

    203 papers led
    6 hospitals
  10. China Medical University (Shenyang)

    中国医科大学Shenyang

    198 papers led
    6 hospitals
  11. Soochow University

    苏州大学Suzhou

    180 papers led
    6 hospitals
  12. Sichuan University (West China)

    四川大学华西Chengdu

    179 papers led
    6 hospitals
  13. Nanchang University

    南昌大学Nanchang

    173 papers led
    6 hospitals
  14. Qingdao University

    青岛大学Qingdao

    170 papers led
    6 hospitals
  15. Southern Medical University

    南方医科大学Guangzhou

    162 papers led
    6 hospitals
  16. Shandong First Medical University

    山东第一医科大学Jinan

    153 papers led
    6 hospitals
  17. Wenzhou Medical University

    温州医科大学Wenzhou

    146 papers led
    6 hospitals
  18. Nanjing University

    南京大学Nanjing

    145 papers led
    6 hospitals
  19. Hebei Medical University

    河北医科大学Shijiazhuang

    143 papers led
    6 hospitals
  20. Shandong University

    山东大学Jinan

    141 papers led
    6 hospitals
  21. Chinese PLA General Hospital

    中国人民解放军总医院Beijing

    140 papers led
    1 hospital
  22. Huazhong Univ. of Sci. & Tech. – Tongji Medical College

    华中科技大学同济医学院Wuhan

    136 papers led
    6 hospitals
  23. Anhui Medical University

    安徽医科大学Hefei

    132 papers led
    6 hospitals
  24. Harbin Medical University

    哈尔滨医科大学Harbin

    125 papers led
    6 hospitals
  25. Capital Medical University

    首都医科大学Beijing

    113 papers led
    6 hospitals
  26. Tianjin Medical University

    天津医科大学Tianjin

    113 papers led
    3 hospitals
  27. Central South University (Xiangya)

    中南大学湘雅Changsha

    107 papers led
    6 hospitals
  28. Nantong University

    南通大学Nantong

    107 papers led
    1 hospital
  29. University of Chinese Academy of Sciences

    中国科学院大学Beijing

    106 papers led
    1 hospital
  30. Wuhan University

    武汉大学Wuhan

    104 papers led
    3 hospitals
  31. Xi'an Jiaotong University

    西安交通大学Xi'an

    101 papers led
    6 hospitals
  32. Jilin University

    吉林大学Changchun

    97 papers led
    5 hospitals
  33. Tongji University

    同济大学Shanghai

    84 papers led
    6 hospitals
  34. Air Force Medical University

    空军军医大学Xi'an

    77 papers led
    6 hospitals
  35. Chongqing Medical University

    重庆医科大学Chongqing

    77 papers led
    6 hospitals
  36. Xiamen University

    厦门大学Xiamen

    72 papers led
    6 hospitals
  37. Guangxi Medical University

    广西医科大学Nanning

    68 papers led
    6 hospitals
  38. 59 papers led
    6 hospitals
  39. Army Medical University

    陆军军医大学Chongqing

    56 papers led
    5 hospitals
  40. Xuzhou Medical University

    徐州医科大学Xuzhou

    56 papers led
    6 hospitals
  41. Naval Medical University

    海军军医大学Shanghai

    55 papers led
    4 hospitals
  42. Ningxia Medical University

    宁夏医科大学Yinchuan

    49 papers led
    5 hospitals
  43. Guangzhou Medical University

    广州医科大学Guangzhou

    41 papers led
    6 hospitals
  44. Southwest Medical University

    西南医科大学Luzhou

    39 papers led
    1 hospital
  45. 39 papers led
    3 hospitals
  46. Jiangnan University

    江南大学Wuxi

    37 papers led
    4 hospitals
  47. Jinan University

    暨南大学Guangzhou

    34 papers led
    6 hospitals
  48. Shenzhen University

    深圳大学Shenzhen

    33 papers led
    6 hospitals
  49. Bengbu Medical University

    蚌埠医科大学Bengbu

    31 papers led
    1 hospital
  50. 30 papers led
    1 hospital
  51. Chongqing University

    重庆大学Chongqing

    29 papers led
    6 hospitals
  52. Xinjiang Medical University

    新疆医科大学Urumqi

    27 papers led
    6 hospitals
  53. Shantou University Medical College

    汕头大学医学院Shantou

    26 papers led
    1 hospital
  54. Guizhou Medical University

    贵州医科大学Guiyang

    25 papers led
    1 hospital
  55. Kunming Medical University

    昆明医科大学Kunming

    24 papers led
    6 hospitals
  56. Chengdu University

    成都大学Chengdu

    15 papers led
    1 hospital
  57. Guangdong Medical University

    广东医科大学Zhanjiang

    14 papers led
    3 hospitals
  58. Guilin Medical University

    桂林医学院Guilin

    9 papers led
    1 hospital
  59. Guangdong Pharmaceutical University

    广东药科大学Guangzhou

    6 papers led
    2 hospitals

408

open trials on stomach cancer in China

Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 8 Nov 2026, with at least one listed hospital as lead sponsor or site. 315 of them are led by a listed hospital. Check the registry for the current status. Whether someone can take part is decided by the study team.

Trials registered only in China’s own registry (ChiCTR) are not included. Questions to check before asking about a trial

What the phases mean (US National Cancer Institute)

  1. Recruiting
    The Application of 18F-G1 PET/CT Targeting Granzyme B in the Pan-cancer Immunotherapy
    Phase
    Not given
    Started
    2026-09
    Registry
    NCT07039474

    Age 18 years to 75 years (registered criteria)

    Led by Peking University First HospitalBeijing

  2. Recruiting
    A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
    Phase
    Phase 2/Phase 3
    Started
    2026-03
    Registry
    NCT07221149

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Nanning, Shanghai

  3. Recruiting
    Single-port Robotic Radical Gastrectomy for Gastric Cancer
    Phase
    N/A
    Started
    2026-07
    Registry
    NCT07237126

    Age 18 years to 75 years (registered criteria)

    Led by Daping Hospital, Army Medical UniversityChongqing

  4. Recruiting
    SHR-1701 + Rivoceranib (± SHR-2554) in Advanced GC After First-Line Immunotherapy Failure
    Phase
    Phase 2
    Started
    2026-01
    Registry
    NCT07311408

    Age 18 years to Not stated (registered criteria)

    Led by Liaoning Cancer Hospital & InstituteShenyang

  5. Recruiting
    A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
    Phase
    Phase 3
    Started
    2026-01
    Registry
    NCT07315750

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  6. Recruiting
    Remimazolam for Reducing Postoperative Delirium in Elderly Patients Undergoing Laparoscopic Gastrectomy
    Phase
    N/A
    Started
    2026-01
    Registry
    NCT07351474

    Age 65 years to 100 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  7. Recruiting
    A First-in-human Study of 3H-10000 in Patients With Unresectable or Metastatic Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2026-01
    Registry
    NCT07354711

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  8. Recruiting
    LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma
    Phase
    Phase 3
    Started
    2026-04
    Registry
    NCT07362186

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  9. Recruiting
    Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
    Phase
    Phase 3
    Started
    2026-04
    Registry
    NCT07385703

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 64 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Changzhou, Chengde, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Nanchang, Nanchong, Nanjing, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xuzhou, Yangzhou, Zhengzhou

  10. Recruiting
    Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
    Phase
    Phase 2/Phase 3
    Started
    2026-05
    Registry
    NCT07392892

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesChengdu, Guangzhou, Shanghai, Wuhan

  11. Recruiting
    DeepComp for Prediction of Gastric Cancer Postoperative Complications (DeepComp-Prospective)
    Phase
    Not given
    Started
    2026-03
    Registry
    NCT07401173

    Age 18 years to 85 years (registered criteria)

    Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang

  12. Recruiting
    Multimodal AI for Predicting Response to Neoadjuvant Immunotherapy in Gastric Cancer (PRISM-GC)
    Phase
    Not given
    Started
    2026-02
    Registry
    NCT07401199

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesShijiazhuang, Wuhan

  13. Recruiting
    Full-time RDI for ESD: Impact on Major Adverse Events and Procedure Time
    Phase
    N/A
    Started
    2026-03
    Registry
    NCT07401303

    Age 18 years to 75 years (registered criteria)

    Led by Xijing HospitalXi'an

  14. Recruiting
    Digital Rehabilitation for Gastric Cancer Surgery After Neoadjuvant Therapy
    Phase
    N/A
    Started
    2026-03
    Registry
    NCT07441850

    Age 18 years to 70 years (registered criteria)

    Led by Beijing Friendship HospitalBeijing

  15. Recruiting
    SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer
    Phase
    Phase 2
    Started
    2026-04
    Registry
    NCT07464756

    Age 18 years to Not stated (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  16. Recruiting
    Disitamab Vedotin Combined With SOX Regimen Versus SOX Alone as Adjuvant Therapy for HER2-Moderate/High Expressing Stage Ⅲ Gastric Cancer: A Prospective, Multicenter, Randomized, Phase Ⅱ Clinical Trial
    Phase
    Phase 2
    Started
    2026-03
    Registry
    NCT07474324

    Age 18 years to 75 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  17. Recruiting
    IBI343 in Combination Therapy for Advanced Malignant Solid Tumors
    Phase
    Phase 2
    Started
    2026-04
    Registry
    NCT07483554

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteHangzhou

  18. Recruiting
    A Clinical Study of Sintilimab Combined With Chemothrapy Versus Chemotherapy as Adjuvant Therapy for Gastric/Gastroesophageal Junction Adenocarcinoma
    Phase
    Phase 2
    Started
    2026-01
    Registry
    NCT07492615

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  19. Recruiting
    Large Language Models Assist in Tumor MDT
    Phase
    N/A
    Started
    2026-01
    Registry
    NCT07504367

    Age 25 years to 33 years (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  20. Recruiting
    Dynamic Circulating Tumor DNA Monitoring to Guide Systemic Therapy in Gastric Cancer
    Phase
    Phase 2
    Started
    2026-01
    Registry
    NCT07517107

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  21. Recruiting
    A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment
    Phase
    Phase 3
    Started
    2026-05
    Registry
    NCT07518147

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  22. Recruiting
    Clinical Study of Adebrelimab Therapy in the Perioperative Treatment of Gastric Cancer or Gastroesophageal Junction Cancer
    Phase
    Phase 3
    Started
    2026-05
    Registry
    NCT07522151

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  23. Recruiting
    Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2026-03
    Registry
    NCT07523529

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenzhen

  24. Recruiting
    AI-assisted Decision-making of Reoperation for Postoperative Bleeding of Gastric Cancer
    Phase
    Not given
    Started
    2026-04
    Registry
    NCT07525765

    Age 18 years to 90 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  25. Recruiting
    Safety and Efficacy of Leucine-Restricted Diet Combined With Chemotherapy and Immunotherapy in Advanced Gastric Cancer
    Phase
    Phase 2
    Started
    2026-01
    Registry
    NCT07537348

    Age 18 years to 70 years (registered criteria)

    Led by Qilu Hospital of Shandong UniversityJinan

  26. Recruiting
    Safety and Efficacy of Leucine-Restricted Diet Combined With Neoadjuvant Chemotherapy and Immunotherapy in Gastric Cancer
    Phase
    Phase 2
    Started
    2026-01
    Registry
    NCT07537361

    Age 18 years to 70 years (registered criteria)

    Led by Qilu Hospital of Shandong UniversityJinan

  27. Recruiting
    Dual-target CLDN18.2/HER2 CAR-NK Cells for Advanced Gastric/GEJ Cancer
    Phase
    Phase 1/Phase 2
    Started
    2026-03
    Registry
    NCT07551362

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenzhen

  28. Recruiting
    AI Model for Early Gastric Cancer Diagnosis Using Endoscopic Imaging
    Phase
    Not given
    Started
    2026-05
    Registry
    NCT07551466

    Age 18 years to 80 years (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  29. Recruiting
    Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric Cancer
    Phase
    N/A
    Started
    2026-06
    Registry
    NCT07552402

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Chengdu, Dalian, Fuzhou, Hangzhou, Nanning, Shanghai, Shijiazhuang, Suzhou, Wuhan, Yinchuan

  30. Recruiting
    LM-302 and S-1 Plus Intraperitoneal Paclitaxel With or Without Cadonilimab for Claudin 18.2-positive Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis: a Prospective, Exploratory Study
    Phase
    Phase 2
    Started
    2026-04
    Registry
    NCT07556640

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  31. Recruiting
    Evaluation of Fecal Multi-target Biomarkers in the Screening of Digestive Tract Cancers
    Phase
    Not given
    Started
    2026-08
    Registry
    NCT07600125

    Age 18 years to Not stated (registered criteria)

    Led by Xijing Hospital; 3 listed hospitals as study sitesDalian, Qingdao, Wuxi, Xi'an

  32. Recruiting
    Laparoscopic-endoscopic Surgery Assisted Sentinel Lymph Node Navigation Surgery for Early Gastric Cancer
    Phase
    N/A
    Started
    2026-05
    Registry
    NCT07615374

    Age not stated (registered criteria)

    Led by First Hospital of Jilin UniversityChangchun

  33. Recruiting
    HIPEC Priming Followed by Serplulimab Plus SOX/XELOX in Locally Advanced Gastric Cancer
    Phase
    Phase 2
    Started
    2026-07
    Registry
    NCT07621484

    Age 18 years to 75 years (registered criteria)

    Led by Changzheng HospitalShanghai

  34. Recruiting
    Comparison of Double-tract and Tubular Gastric Anastomosis in Proximal Gastric Cancer
    Phase
    N/A
    Started
    2026-05
    Registry
    NCT07635836

    Age 18 years to 75 years (registered criteria)

    Led by Qilu Hospital of Shandong UniversityJinan

  35. Recruiting
    Two-component Radiology-guided Autonomous Cascade Engine (TRACE)
    Phase
    N/A
    Started
    2026-06
    Registry
    NCT07651644

    Age not stated (registered criteria)

    Led by Liaoning Cancer Hospital & InstituteShenyang

  36. Recruiting
    A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer
    Phase
    Phase 3
    Started
    2026-07
    Registry
    NCT07673887

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  37. Recruiting
    Chemoradiotherapy and SHR-1701 in Patients With Unresectable Gastric Cancer
    Phase
    Phase 2
    Started
    2026-07
    Registry
    NCT07689851

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Shenzhen, Taiyuan

  38. Recruiting
    Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma
    Phase
    Phase 3
    Started
    2026-09
    Registry
    NCT07700979

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Guangzhou, Shanghai

  39. Recruiting
    A Study to Evaluate the Human Biodistribution and Dosimetry of the Radionuclide Labeled IR199 in Patients With Gastric Cancer and Pancreatic Cancer
    Phase
    Early phase 1
    Started
    2026-06
    Registry
    NCT07707531

    Age 18 years to Not stated (registered criteria)

    Led by Huashan HospitalShanghai

  40. Recruiting
    Clinical Study on Using Laparoscopic Sentinel Lymph Node Navigation Combined With Dual Endoscopy Surgery for Early Gastric Cancer
    Phase
    N/A
    Started
    2026-01
    Registry
    NCT07708012

    Age 18 years to 80 years (registered criteria)

    Led by Affiliated Hospital of Qingdao UniversityQingdao

  41. Recruiting
    TEAS Timing for Gastrectomy Recovery (TEAS-TIME Trial)
    Phase
    N/A
    Started
    2026-07
    Registry
    NCT07714980

    Age 18 years to 80 years (registered criteria)

    Led by Affiliated Hospital of Qingdao University; 5 listed hospitals as study sitesBeijing, Qingdao, Weifang, Weihai, Yantai

  42. Recruiting
    Retrospective Analysis of Early Gastric Cancer Patients Based on Prospective Clinical Dataset
    Phase
    Not given
    Started
    2026-05
    Registry
    NCT07747688

    Age 18 years to 90 years (registered criteria)

    Led by Beijing Friendship HospitalBeijing

  43. Recruiting
    CT Imaging and Clinical Features to Predict Outcomes in Patients With Gastric Cancer
    Phase
    Not given
    Started
    2026-04
    Registry
    NCT07776067

    Age 18 years to Not stated (registered criteria)

    Led by Union HospitalWuhan

  44. Recruiting
    A Clinical Study Comparing Anti-HER2 Therapy Combined With Chemotherapy to Chemotherapy Alone as Adjuvant Therapy Following Surgery for Stage IB-II Gastric Cancer With High HER2 Expression.
    Phase
    Phase 2
    Started
    2026-07
    Registry
    NCT07788196

    Age 18 years to Not stated (registered criteria)

    Led by Xijing HospitalXi'an

  45. Recruiting
    Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy
    Phase
    Phase 3
    Started
    2026-12
    Registry
    NCT07789184

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 25 listed hospitals as study sitesBeijing, Changchun, Chongqing, Dalian, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Qingdao, Shanghai, Tianjin, Urumqi, Wuhan, Xi'an

  46. Recruiting
    Image-Guided Platform-Assisted Sentinel Lymph Node Retrieval in Early Gastric Cancer
    Phase
    N/A
    Started
    2026-08
    Registry
    NCT07835087

    Age 18 years to 80 years (registered criteria)

    Led by Beijing Friendship HospitalBeijing

  47. Recruiting
    Silent Evaluation of DeepTRG for Assessing Tumor Response After Preoperative Treatment in Stomach and Gastroesophageal Junction Cancer
    Phase
    Not given
    Started
    2026-09
    Registry
    NCT07849608

    Age 18 years to Not stated (registered criteria)

    Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang

  48. Recruiting
    Anti-PD-1 in Combination With Systemic Chemotherapy With Nab-paclitaxel Intraperitoneal Infusion for Untreated Advanced Gastric Cancer With Malignant Ascites
    Phase
    Not given
    Started
    2026-07
    Registry
    NCT07855640

    Age 18 years to 75 years (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  49. Recruiting
    LECS Combined With LSNNS for Early Gastric Cancer (LENS Trial)
    Phase
    Not given
    Started
    2026-08
    Registry
    NCT07857668

    Age 20 years to 80 years (registered criteria)

    Led by Peking University People's HospitalBeijing

  50. Recruiting
    68Ga-labeled Cholecystokinin Receptor (CCK2R) Targeted Molecular Probes in Early Tumor Diagnosis
    Phase
    Not given
    Started
    2026-08
    Registry
    NCT07914764

    Age 18 years to 75 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  51. Recruiting
    Systemic Application of Cadonilimab, LM-302, and S-1 Combined With Intraperitoneal Infusion of Paclitaxel for the Treatment of Claudin 18.2-positive Gastric Cancer With Peritoneal Metastasis
    Phase
    Phase 2
    Started
    2025-02
    Registry
    NCT06519591

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  52. Recruiting
    A Clinical Study Evaluating the Efficacy of Systemic Chemotherapy and Immune Checkpoint Inhibitors Combined With Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Gastric Cancer Patients With Peritoneal Metastasis
    Phase
    Phase 2
    Started
    2025-02
    Registry
    NCT06685887

    Age 18 years to 75 years (registered criteria)

    Led by Union HospitalWuhan

  53. Recruiting
    Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
    Phase
    Phase 3
    Started
    2025-02
    Registry
    NCT06731478

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changzhou, Fuzhou, Hangzhou, Harbin, Hefei, Jinan, Lanzhou, Linyi, Shanghai, Shenyang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xuzhou, Yinchuan, Zhengzhou

  54. Recruiting
    A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
    Phase
    Phase 2
    Started
    2025-02
    Registry
    NCT06760819

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesBeijing, Changsha, Hangzhou, Shanghai

  55. Recruiting
    QL1706 Combined With SOX Used in Theperioperative Treatment
    Phase
    Phase 1/Phase 2
    Started
    2025-03
    Registry
    NCT06766305

    Age 18 years to 75 years (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  56. Recruiting
    HS-10502 Combination Treatment in Patients With Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2025-05
    Registry
    NCT06769425

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  57. Recruiting
    BC001 in Combination with Sintilimab and XELOX in the Treatment of HER-2 Negative Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma.
    Phase
    Phase 1
    Started
    2025-02
    Registry
    NCT06773312

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  58. Recruiting
    Robotic Versus Laparoscopic Radical Surgery for Locally Advanced Gastric Cancer
    Phase
    N/A
    Started
    2025-02
    Registry
    NCT06791538

    Age 18 years to 75 years (registered criteria)

    Led by Southwest Hospital, Army Medical UniversityChongqing

  59. Recruiting
    Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma
    Phase
    Phase 3
    Started
    2025-06
    Registry
    NCT06793917

    Age 18 years to 70 years (registered criteria)

    Led by Fujian Cancer HospitalFuzhou

  60. Recruiting
    COMBO Endoscopy Oropharyngeal Airway Reduces Hypoxia During Sedated Gastrointestinal Endoscopy in Obese Patients: A Multicenter, Randomized, Controlled Clinical Trial
    Phase
    N/A
    Started
    2025-04
    Registry
    NCT06796764

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHangzhou

  61. Recruiting
    Nanocrystalline Megestrol for First-line Treatment of Advanced Gastric or Colorectal Cancer With Cancer-related Fatigue
    Phase
    N/A
    Started
    2025-01
    Registry
    NCT06830018

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenyang

  62. Recruiting
    Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
    Phase
    Not given
    Started
    2025-02
    Registry
    NCT06846996

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 32 listed hospitals as study sitesBeijing, Changchun, Fuzhou, Guangzhou, Haikou, Hangzhou, Nanjing, Shanghai, Shantou, Shenyang, Taiyuan, Taizhou, Tianjin, Xuzhou, Zhengzhou

  63. Recruiting
    SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors
    Phase
    Phase 1
    Started
    2025-02
    Registry
    NCT06873659

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Jinan, Lanzhou, Nanjing, Shanghai, Xi'an

  64. Recruiting
    Exploratory Study on the Efficacy of Betaine Hydrochloride in Treating Autoimmune Gastritis
    Phase
    N/A
    Started
    2025-01
    Registry
    NCT06881511

    Age 18 years to 80 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  65. Recruiting
    ctDNA-MRD Monitoring After Resection in Gastric Cancer
    Phase
    Not given
    Started
    2025-04
    Registry
    NCT06893133

    Age 18 years to Not stated (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  66. Recruiting
    A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
    Phase
    Phase 3
    Started
    2025-05
    Registry
    NCT06901531

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Hangzhou, Harbin, Hefei, Shanghai, Shijiazhuang, Tianjin, Wuhan, Xining, Zhengzhou

  67. Recruiting
    Metabolomic and Lipidomic Analysis Predicts Immunotherapy-related Adverse Events in Gastric Cancer Patients
    Phase
    Not given
    Started
    2025-02
    Registry
    NCT06915389

    Age 18 years to 80 years (registered criteria)

    Led by Qinghai Red Cross HospitalXining

  68. Recruiting
    Neoadjuvant Apatinib Combined With Sintilimab and Perioperative SOX Versus Neoadjuvant Sintilimab Combined With Perioperative SOX for Intestinal Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
    Phase
    Phase 3
    Started
    2025-04
    Registry
    NCT06925243

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesGuangzhou, Lanzhou

  69. Recruiting
    Real-World Study on Nano-Crystalline Megestrol Acetate for Cachexia in TKI-Treated Advanced Digestive Tumors
    Phase
    Not given
    Started
    2025-03
    Registry
    NCT06940102

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenyang

  70. Recruiting
    Clinical Outcomes of Indocyanine Green Tracer Using in Laparoscopic Gastrectomy With Extended Lymphadenectomy Beyond D2 for Locally Advanced Gastric Cancer (FUGES-30)
    Phase
    Not given
    Started
    2025-05
    Registry
    NCT06945718

    Age 18 years to 75 years (registered criteria)

    Led by Fujian Medical University Union HospitalFuzhou

  71. Recruiting
    Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors
    Phase
    Phase 2
    Started
    2025-06
    Registry
    NCT06947291

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteHangzhou

  72. Recruiting
    Neoadjuvant Cadonilimab Combined With Perioperative Oxaliplatin Plus S1 for Diffuse or Mixed Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
    Phase
    Phase 3
    Started
    2025-05
    Registry
    NCT06949033

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesGuangzhou, Lanzhou

  73. Recruiting
    Bovine Reinforcement in Stomach, Colorectal and Lung Operation
    Phase
    Phase 3
    Started
    2025-05
    Registry
    NCT06968221

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  74. Recruiting
    Investigating Multigene Methylation Dynamics in Treatment Response Surveillance for Gastric Cancer
    Phase
    Not given
    Started
    2025-05
    Registry
    NCT06979895

    Age 18 years to 75 years (registered criteria)

    Led by Xijing Hospital; 1 listed hospital as study siteXi'an

  75. Recruiting
    Correlation of Psychological Distress and Immune Checkpoint Inhibitors in Gastric Cancer
    Phase
    Not given
    Started
    2025-01
    Registry
    NCT07003334

    Age 18 years to 75 years (registered criteria)

    Led by Nanfang HospitalGuangzhou

  76. Recruiting
    Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer
    Phase
    Phase 2
    Started
    2025-10
    Registry
    NCT07007182

    Age 18 years to 75 years (registered criteria)

    Led by Shandong Cancer Hospital and InstituteJinan

  77. Recruiting
    Venetoclax + Azacytidine for Newly Diagnosed ETP-like ALL and T-ALL With Myeloid Mutations
    Phase
    Phase 2
    Started
    2025-04
    Registry
    NCT07012447

    Age 14 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  78. Recruiting
    A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma
    Phase
    Phase 3
    Started
    2025-08
    Registry
    NCT07023315

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Fuzhou, Harbin, Shanghai, Shijiazhuang

  79. Recruiting
    IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric Cancer
    Phase
    Phase 1/Phase 2
    Started
    2025-06
    Registry
    NCT07025889

    Age 18 years to 75 years (registered criteria)

    Led by Ruijin HospitalShanghai

  80. Recruiting
    Perioperative Treatment of Combined Radiotherapy With SOX, Apatinib and Camrelizumab for Oesophagogastric Cancer
    Phase
    Phase 2
    Started
    2025-06
    Registry
    NCT07026149

    Age 18 years to 75 years (registered criteria)

    Led by Ruijin HospitalShanghai

  81. Recruiting
    Feasibility of Enhanced Recovery After Surgery Without Prophylactic Abdominal Drainage Tubes After Laparoscopic Distal Gastrectomy For Gastric Cancer
    Phase
    Phase 3
    Started
    2025-06
    Registry
    NCT07029269

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesFuzhou, Guangzhou, Hangzhou, Lanzhou, Xi'an

  82. Recruiting
    A Cohort Study of Mobile Capsule Gastroscopy for Gastric Pathologies Screening
    Phase
    Not given
    Started
    2025-06
    Registry
    NCT07032961

    Age 45 years to Not stated (registered criteria)

    Led by Nanfang HospitalGuangzhou

  83. Recruiting
    A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2025-07
    Registry
    NCT07066657

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Changsha, Chongqing, Hangzhou, Harbin, Shanghai, Wuhan, Zhengzhou

  84. Recruiting
    Clinical Evaluation of GRAPE Model for Gastric Cancer Screening
    Phase
    Not given
    Started
    2025-05
    Registry
    NCT07067983

    Age 18 years to 80 years (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  85. Recruiting
    Development and Validation of Metabolic Biomarkers for Early Diagnosis, Prognosis, and Recurrence of Colorectal Cancer:MetBio-CRC
    Phase
    Not given
    Started
    2025-06
    Registry
    NCT07068529

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  86. Recruiting
    The Construction of a Predictive Model for Gastric Cancer Immunotherapy Response Based on Tumor-Infiltrating Lymphocytes (TILs) and Histone H3K4me3 in the Tumor Microenvironment
    Phase
    Not given
    Started
    2025-01
    Registry
    NCT07069842

    Age 18 years to 75 years (registered criteria)

    Led by Changzhi People's Hospital, Changzhi Medical CollegeChangzhi

  87. Recruiting
    A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
    Phase
    Phase 1/Phase 2
    Started
    2025-08
    Registry
    NCT07070232

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesChongqing, Hangzhou, Tianjin, Wuhan

  88. Recruiting
    Development and Validation of Metabolic Biomarkers for Early Diagnosis, Prognosis, and Recurrence of Gastric Cancer:MetBio-GC
    Phase
    Not given
    Started
    2025-06
    Registry
    NCT07076979

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  89. Recruiting
    Multicenter Observational Study of Multimodal AI for Upper GI Mesenchymal Tumor Diagnosis
    Phase
    Not given
    Started
    2025-07
    Registry
    NCT07078136

    Age 18 years to Not stated (registered criteria)

    Led by Tongji HospitalWuhan

  90. Recruiting
    Shenqi Fuwei Mixture Combined With Chemotherapy Neoadjuvant Therapy for Locally Advanced Gastric Cancer
    Phase
    N/A
    Started
    2025-05
    Registry
    NCT07098026

    Age 18 years to 75 years (registered criteria)

    Led by Hunan Cancer HospitalChangsha

  91. Recruiting
    Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma
    Phase
    Phase 2
    Started
    2025-09
    Registry
    NCT07102901

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHarbin, Zhengzhou

  92. Recruiting
    A Phase III Randomized Study in CLDN18.2-positive Unresectable Locally Advanced Gastric Cancer Patients
    Phase
    Phase 3
    Started
    2025-08
    Registry
    NCT07103668

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  93. Recruiting
    Development and Validation of a Risk Prediction Model for Gastric Retention in Patients Undergoing Sedated Gastroscopy
    Phase
    Not given
    Started
    2025-08
    Registry
    NCT07104214

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  94. Recruiting
    A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ Cancer
    Phase
    Phase 2
    Started
    2025-08
    Registry
    NCT07110571

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHangzhou, Shijiazhuang

  95. Recruiting
    A Study of LY4257496 in Participants With Cancer (OMNIRAY)
    Phase
    Phase 1
    Started
    2025-08
    Registry
    NCT07114601

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Tianjin

  96. Recruiting
    Multimodal Deep Learning for Lymph Node Metastasis Prediction and Physician Performance Assessment in T1 Gastric Cancer
    Phase
    Not given
    Started
    2025-01
    Registry
    NCT07124754

    Age 18 years to Not stated (registered criteria)

    Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang

  97. Recruiting
    Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Cancer
    Phase
    Phase 2
    Started
    2025-12
    Registry
    NCT07127822

    Age 18 years to Not stated (registered criteria)

    Led by Peking University Cancer Hospital; 8 listed hospitals as study sitesBeijing, Chengdu, Harbin, Qingdao, Shijiazhuang, Taiyuan, Tianjin, Xi'an, Zhengzhou

  98. Recruiting
    The Clinical Significance of Examining Metastatic Lymph Nodes in Individual Gastric Mesenteries in the Patients With Gastric Cancer Undergoing Gastrectomy
    Phase
    Not given
    Started
    2025-10
    Registry
    NCT07139418

    Age 18 years to 85 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  99. Recruiting
    Safety Comparison of Total Laparoscopic Proximal Gastrectomy With or Without Preservation of the Celiac Branch of the Vagus Nerve for Early Upper Gastric Cancer: A Randomized Controlled Clinical Trial
    Phase
    N/A
    Started
    2025-01
    Registry
    NCT07142122

    Age 18 years to 75 years (registered criteria)

    Led by Fujian Cancer HospitalFuzhou

  100. Recruiting
    Neoadjuvant Radiotherapy Plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and GE-junction Cancer : A Randomized, Two-arm, Prospective Trial (TRIUNITE-05)
    Phase
    Phase 2
    Started
    2025-07
    Registry
    NCT07165847

    Age 18 years to Not stated (registered criteria)

    Led by Daping Hospital, Army Medical UniversityChongqing

  101. Recruiting
    Safety and Efficacy of NK510 to Treat Gastric Cancer and Colorectal Cancer
    Phase
    Early phase 1
    Started
    2025-10
    Registry
    NCT07166263

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteNanjing

  102. Recruiting
    Combination of COMBO Endoscopy Oropharyngeal Airway and HFNC Oxygenation in Sedated Gastrointestinal Endoscopy for Morbidly Obese Patients
    Phase
    N/A
    Started
    2025-10
    Registry
    NCT07175155

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital, Zhejiang University; 2 listed hospitals as study sitesBeijing, Hangzhou, Taizhou

  103. Recruiting
    The PRE-VAIL Study
    Phase
    N/A
    Started
    2025-09
    Registry
    NCT07176624

    Age 18 years to Not stated (registered criteria)

    Led by First Hospital of Jilin UniversityChangchun

  104. Recruiting
    The Possible Range of No.4sb Lymph Node Dissection of Locally Advanced Distal Gastric Cancer
    Phase
    Not given
    Started
    2025-08
    Registry
    NCT07183150

    Age 18 years to 80 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  105. Recruiting
    Conversion Therapy With RC48, Sintilimab, and SOX for HER2 1+/2+ Unresectable Gastric Cancer
    Phase
    Phase 2
    Started
    2025-09
    Registry
    NCT07194005

    Age 18 years to 70 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  106. Recruiting
    The Safety and Clinical Efficacy of RAK Cell Therapy in Late-stage Gastric Cancer: A Randomized Controlled Trial
    Phase
    Phase 2
    Started
    2025-07
    Registry
    NCT07212933

    Age 18 years to 70 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  107. Recruiting
    A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
    Phase
    Phase 1
    Started
    2025-10
    Registry
    NCT07213791

    Age 18 years to Not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  108. Recruiting
    AI-Assisted Detection and Staging of Gastric Cancer Using Contrast-Enhanced CT
    Phase
    Not given
    Started
    2025-08
    Registry
    NCT07250347

    Age 18 years to 85 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  109. Recruiting
    Distribution Characteristics of Helicobacter Pylori
    Phase
    Not given
    Started
    2025-10
    Registry
    NCT07253948

    Age 18 years to 80 years (registered criteria)

    Led by First Hospital of Jilin UniversityChangchun

  110. Recruiting
    A Phase II, Multicenter, Randomized, Controlled Clinical Study Comparing the Efficacy and Safety of Sintilimab Plus SOX Versus SOX Alone as Adjuvant Therapy for PD-L1-Positive, Stage pN3 Gastric Cancer
    Phase
    Phase 2
    Started
    2025-10
    Registry
    NCT07263386

    Age 18 years to 75 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  111. Recruiting
    Phase II Trial of Neoadjuvant Thymalfasin, PD-1 Inhibitor, and Chemoradiotherapy for cStage III GEJ Adenocarcinoma
    Phase
    Phase 2
    Started
    2025-12
    Registry
    NCT07277439

    Age 18 years to 75 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  112. Recruiting
    Iparomlimab and Tuvonralimab Combined With Apatinib and Irinotecan Hydrochloride for the Treatment of Advanced Alpha-fetoprotein-producing Gastric Cancer (AFPGC)
    Phase
    Phase 2
    Started
    2025-09
    Registry
    NCT07289997

    Age 18 years to Not stated (registered criteria)

    Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang

  113. Recruiting
    Novel Humanized Ferritin-Based NIR Fluorescent Probe for Identifying Sentinel Lymph Node Metastasis in Early Gastric Cancer
    Phase
    Not given
    Started
    2025-07
    Registry
    NCT07294638

    Age 18 years to Not stated (registered criteria)

    Led by Nanfang HospitalGuangzhou

  114. Recruiting
    PDL1/TGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric Cancer
    Phase
    Phase 2
    Started
    2025-06
    Registry
    NCT07294664

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou

  115. Recruiting
    Clinical Trial on the Safety, Tolerance and Preliminary Efficacy of XH001 Injection Combined With Neoantigen Vaccine-induced Tumor-specific T-cell Injection in Advanced Gastric Cancer
    Phase
    Phase 1
    Started
    2025-12
    Registry
    NCT07298200

    Age 18 years to 70 years (registered criteria)

    Led by Nanjing Drum Tower HospitalNanjing

  116. Recruiting
    Clinical Application of PET Imaging Targeting CLDN18.2 in Malignant Tumors
    Phase
    Not given
    Started
    2025-09
    Registry
    NCT07301814

    Age 18 years to Not stated (registered criteria)

    Led by Union HospitalWuhan

  117. Recruiting
    High-Flow Nasal Cannula for Preventing Hypoxia During Sedated Endoscopy in High-Risk Obstructive Sleep Apnea Patients
    Phase
    N/A
    Started
    2025-12
    Registry
    NCT07307560

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  118. Recruiting
    Iparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy for Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer
    Phase
    Phase 2
    Started
    2025-11
    Registry
    NCT07315854

    Age 18 years to 80 years (registered criteria)

    Led by Beijing Friendship HospitalBeijing

  119. Recruiting
    Perioprative Study of IBI363 in Patients With MHC-II-Negative Locally Advanced Gastric Cancer
    Phase
    Phase 2
    Started
    2025-11
    Registry
    NCT07325630

    Age 18 years to 75 years (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  120. Recruiting
    Adebrelimab Plus Apatinib Combined With SOX Regimen as Conversion Therapy for Gastric Cancer
    Phase
    Phase 2
    Started
    2025-05
    Registry
    NCT07353684

    Age 18 years to 75 years (registered criteria)

    Led by Beijing Friendship HospitalBeijing

  121. Recruiting
    Laryngopharyngeal Injury After Endotracheal Intubation Under General Anesthesia
    Phase
    Not given
    Started
    2025-11
    Registry
    NCT07359586

    Age not stated (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  122. Recruiting
    Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer
    Phase
    Phase 3
    Started
    2025-12
    Registry
    NCT07366528

    Age 18 years to 80 years (registered criteria)

    Led by Ruijin Hospital; 3 listed hospitals as study sitesShanghai

  123. Recruiting
    An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2025-12
    Registry
    NCT07371663

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Hangzhou, Zhengzhou

  124. Recruiting
    Safety and Efficacy of Fruquintinib Plus Nab-Paclitaxel and Iparomlimab and Tuvonralimab Injection in the Second-Line Treatment for Immunotherapy-experienced Advanced Gastric Cancer
    Phase
    Phase 2
    Started
    2025-12
    Registry
    NCT07392346

    Age 18 years to Not stated (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  125. Recruiting
    RCT of EFTR Versus STER for GIST Treatment
    Phase
    N/A
    Started
    2025-02
    Registry
    NCT07411118

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  126. Recruiting
    Single-port Versus Conventional Laparoscopic Surgery for Radical Proximal Gastric Cancer: A Randomized Controlled Trial
    Phase
    N/A
    Started
    2025-11
    Registry
    NCT07586384

    Age 18 years to 80 years (registered criteria)

    Led by First Affiliated Hospital of Wenzhou Medical UniversityWenzhou

  127. Recruiting
    To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors
    Phase
    Phase 1
    Started
    2025-08
    Registry
    NCT07594964

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing

  128. Recruiting
    A IIT Study of 177Lu-DOTA-SNA040
    Phase
    Early phase 1
    Started
    2025-11
    Registry
    NCT07595237

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  129. Recruiting
    TAIC FOLFOX for Locally Advanced G/GEJA
    Phase
    Phase 2
    Started
    2025-11
    Registry
    NCT07655024

    Age 18 years to Not stated (registered criteria)

    Led by Guang'anmen HospitalBeijing

  130. Recruiting
    The Necessity of Surgery in Patients With mGC Achieving Radiological Response After Conversion Therapy
    Phase
    Phase 2
    Started
    2025-11
    Registry
    NCT07757165

    Age 18 years to 75 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  131. Recruiting
    A Random, Non-controlled, Open Clinical Study of Apatinib Mesylate Combined With Albumin-bound Paclitaxel ± Adebrelimab in Treating Advanced Second-line Gastric Cancer
    Phase
    Phase 2
    Started
    2025-06
    Registry
    NCT07770113

    Age 18 years to 80 years (registered criteria)

    Led by First Affiliated Hospital of Zhengzhou University; 1 listed hospital as study siteLuoyang, Zhengzhou

  132. Recruiting
    Predicting Efficacy of Preoperative Immunotherapy in Advanced Gastric Cancer
    Phase
    Not given
    Started
    2025-06
    Registry
    NCT07824479

    Age 18 years to 80 years (registered criteria)

    Led by Ruijin HospitalShanghai

  133. Recruiting
    Neoadjuvant Iparomlimab and Tuvonralimab With Nab-P-SOX in Locally Advanced Gastric or Gastroesophageal Junction Cancer
    Phase
    Phase 2
    Started
    2025-02
    Registry
    NCT07867392

    Age 18 years to 75 years (registered criteria)

    Led by Ruijin HospitalShanghai

  134. Recruiting
    Candonilimab Combined With Fruquintinib and Paclitaxel Albumin-Bound as Second-Line Treatment for Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma
    Phase
    Phase 2
    Started
    2025-07
    Registry
    NCT07920224

    Age 18 years to 75 years (registered criteria)

    Led by Union HospitalWuhan

  135. Recruiting
    Exploring the Difference Between Gastric Cardia Cancer and Non-cardia Gastric Cancer Based on Multiomics
    Phase
    Not given
    Started
    2024-03
    Registry
    NCT05812287

    Age 18 years to 75 years (registered criteria)

    Led by Qilu Hospital of Shandong UniversityJinan

  136. Recruiting
    Feasibility and Safety of Robotic Assisted Proximal Gastrectomy With Double-flap Technique for Proximal Early Gastric Cancer
    Phase
    N/A
    Started
    2024-06
    Registry
    NCT05892289

    Age 20 years to 80 years (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  137. Recruiting
    SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen
    Phase
    Phase 3
    Started
    2024-01
    Registry
    NCT06123494

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  138. Recruiting
    Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer
    Phase
    N/A
    Started
    2024-09
    Registry
    NCT06128252

    Age 18 years to 75 years (registered criteria)

    Led by Tangdu Hospital; 11 listed hospitals as study sitesChongqing, Nanjing, Shanghai, Shenyang, Urumqi, Wuhan, Xi'an

  139. Recruiting
    NKG2D/CLDN18.21 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid Tumor
    Phase
    Phase 1
    Started
    2024-11
    Registry
    NCT06134960

    Age 18 years to 75 years (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  140. Recruiting
    Lenvatinib Plus Tislelizumab and CapeOX as First-Line Treatment for Advanced GC/GEJC With Positive PD-L1 and Low TMEscore
    Phase
    Phase 2
    Started
    2024-06
    Registry
    NCT06157996

    Age 18 years to Not stated (registered criteria)

    Led by Nanfang HospitalGuangzhou

  141. Recruiting
    A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
    Phase
    Phase 2
    Started
    2024-02
    Registry
    NCT06172478

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChengdu, Guangzhou

  142. Recruiting
    AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer
    Phase
    Phase 2
    Started
    2024-04
    Registry
    NCT06196697

    Age 18 years to 75 years (registered criteria)

    Led by Harbin Medical University HospitalHarbin

  143. Recruiting
    DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy
    Phase
    Phase 2/Phase 3
    Started
    2024-02
    Registry
    NCT06221748

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changsha, Chengdu, Harbin, Jinan, Kunming, Qingdao, Shanghai, Wuhan, Xiamen, Xuzhou, Zhengzhou

  144. Recruiting
    Early Detection and Post-operative Monitoring of Gastric Cancer
    Phase
    Not given
    Started
    2024-02
    Registry
    NCT06232395

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  145. Recruiting
    A Prospective Study on Esophagogastrostomy by an Innovative Surgical Technique
    Phase
    N/A
    Started
    2024-01
    Registry
    NCT06300879

    Age 18 years to 75 years (registered criteria)

    Led by Huashan HospitalShanghai

  146. Recruiting
    Effectiveness of Risk-based Sequential Screening for Esophageal and Gastric Cancer
    Phase
    N/A
    Started
    2024-06
    Registry
    NCT06306755

    Age 50 years to 69 years (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  147. Recruiting
    Metronomic Capecitabine in Stage III Gastric Cancer
    Phase
    Phase 3
    Started
    2024-03
    Registry
    NCT06313567

    Age 18 years to 80 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  148. Recruiting
    Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
    Phase
    Phase 1/Phase 2
    Started
    2024-06
    Registry
    NCT06324357

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesChangchun, Hangzhou, Harbin, Nanjing, Shanghai, Tianjin, Zhengzhou

  149. Recruiting
    Survival With Olanzapine in Patients With Locally Advanced or Metastatic Upper Gastrointestinal and Lung Cancer
    Phase
    Phase 3
    Started
    2024-03
    Registry
    NCT06338683

    Age 18 years to 80 years (registered criteria)

    Led by Qinghai Red Cross HospitalXining

  150. Recruiting
    Concurrent Chemoradiotherapy Combined With Sintilimab as Neoadjuvant Therapy for GC Patients With PALM
    Phase
    Phase 2
    Started
    2024-04
    Registry
    NCT06341595

    Age 18 years to 75 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  151. Recruiting
    Fecal Microbiota Transplantation (FMT) in Patients With Advanced Gastric Cancer
    Phase
    N/A
    Started
    2024-04
    Registry
    NCT06346093

    Age 18 years to Not stated (registered criteria)

    Led by Changhai HospitalShanghai

  152. Recruiting
    FMT+SOX+Sintilimab As First-line Treatment for Advanced Gastric Cancer
    Phase
    Phase 2
    Started
    2024-06
    Registry
    NCT06405113

    Age 18 years to 80 years (registered criteria)

    Led by Changzhou No.2 People's HospitalChangzhou

  153. Recruiting
    A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction Adenocarcinoma
    Phase
    Phase 2
    Started
    2024-05
    Registry
    NCT06415669

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Xiamen UniversityXiamen

  154. Recruiting
    Fruquintinib and Albumin-paclitaxel Combined With or Without PD-1 Antibody in 2nd-line Treatment of G/GEJ Adenocarcinoma
    Phase
    Not given
    Started
    2024-04
    Registry
    NCT06417892

    Age 18 years to Not stated (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  155. Recruiting
    A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2024-07
    Registry
    NCT06427941

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Hefei, Nanchang, Nanning, Shijiazhuang, Wenzhou, Wuhan, Xuzhou

  156. Recruiting
    Research on Early Diagnosis and Clinical Transformation of Nuclide Probe Based on Bioorthogonal-gastric Cancer Mucin Target Visualization
    Phase
    N/A
    Started
    2024-08
    Registry
    NCT06429891

    Age 18 years to 70 years (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  157. Recruiting
    Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction Adenocarcinoma
    Phase
    Phase 2
    Started
    2024-06
    Registry
    NCT06461910

    Age 18 years to 75 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  158. Recruiting
    Stapler Reinforcement Patches Compared to Standard Staplers in Gastrojejunostomy
    Phase
    N/A
    Started
    2024-05
    Registry
    NCT06464978

    Age 18 years to 85 years (registered criteria)

    Led by Nanchong Central HospitalNanchong

  159. Recruiting
    Synergistic Effects of PD-1 Antibody and Chemotherapy/Targeted Therapy Followed by Surgery-centric Local Treatment in Patients With Limited-metastatic Gastric Cancer
    Phase
    Phase 2
    Started
    2024-11
    Registry
    NCT06468280

    Age 18 years to 79 years (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  160. Recruiting
    Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
    Phase
    Phase 1/Phase 2
    Started
    2024-09
    Registry
    NCT06469944

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesBeijing, Fuzhou, Hangzhou, Nanchang, Shanghai, Urumqi, Xiamen, Zhengzhou

  161. Recruiting
    Short Course Radiotherapy With Sequential Disitamab Vedotin Combined With S-1 and Sintilimab as Whole Course Neoadjuvant Therapy for HER2 Expressed Locally Progressive Gastric Cancer
    Phase
    Phase 2
    Started
    2024-05
    Registry
    NCT06487429

    Age 18 years to 75 years (registered criteria)

    Led by Union HospitalWuhan

  162. Recruiting
    A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Cancer and Other Solid Tumors
    Phase
    Phase 1
    Started
    2024-07
    Registry
    NCT06500052

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  163. Recruiting
    To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer
    Phase
    Phase 2/Phase 3
    Started
    2024-08
    Registry
    NCT06504732

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHarbin, Shenyang

  164. Recruiting
    A Phase II Trial of Perioperative Adebrelimab Combined With XELOX in Resectable Locally Advanced Gastric/Gastroesophageal Junction Cancer (GC/GEJC)
    Phase
    Phase 2
    Started
    2024-07
    Registry
    NCT06506292

    Age 18 years to 75 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  165. Recruiting
    Perioperative Oxaliplatin With S-1 Combined H. Pylori Eradication in the Management of Locally Advanced Gastric Cancer
    Phase
    Phase 2
    Started
    2024-12
    Registry
    NCT06510010

    Age 18 years to 75 years (registered criteria)

    Led by Sixth Affiliated Hospital of Sun Yat-sen UniversityGuangzhou

  166. Recruiting
    A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
    Phase
    Phase 3
    Started
    2024-11
    Registry
    NCT06532006

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 36 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Lanzhou, Luoyang, Nanchang, Nanjing, Qingdao, Shanghai, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Xiamen, Xining, Xuzhou, Yinchuan, Zhengzhou

  167. Recruiting
    Preliminary Study on the Diagnostic Value Comparison of 18F-FAPI-04 PET/CT and PET/MR in Gastric Cancer
    Phase
    Not given
    Started
    2024-01
    Registry
    NCT06543108

    Age 18 years to 90 years (registered criteria)

    Led by Hunan Cancer HospitalChangsha

  168. Recruiting
    A Single-arm, Phase II Exploratory Study of Sintilimab in Combination With Chemoradiotherapy in Elderly Patients With Locally Advanced Gastric Cancer
    Phase
    Phase 2
    Started
    2024-08
    Registry
    NCT06555471

    Age 75 years to Not stated (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  169. Recruiting
    Disitamab Vedotin Combined With Tislelizumab and Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Cancer With HER2 Overexpression
    Phase
    Phase 2
    Started
    2024-09
    Registry
    NCT06560528

    Age 18 years to 75 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  170. Recruiting
    Disitamab Vedotin Plus Trastuzumab in Patients With HER2 Positive GC/GEJ Patiens
    Phase
    Phase 1/Phase 2
    Started
    2024-09
    Registry
    NCT06572319

    Age 18 years to 75 years (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  171. Recruiting
    Immune Checkpoint Inhibitors for Organ Preservation in Non-metastatic dMMR/MSI-H Gastric or Colon Cancers
    Phase
    Phase 2
    Started
    2024-09
    Registry
    NCT06580574

    Age 18 years to Not stated (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  172. Recruiting
    Proximal Gastrectomy vs Total Gastrectomy in Locally Advanced Upper Gastric Cancer After Neoadjuvant Therapy
    Phase
    N/A
    Started
    2024-03
    Registry
    NCT06597227

    Age 18 years to 75 years (registered criteria)

    Led by Tongji HospitalWuhan

  173. Recruiting
    The Role of 18F-FDG&68Ga-FAPI PET/CT in the Assessment of Conversion Therapy Efficacy in Gastric Cancer with Peritoneal Metastasis.
    Phase
    Not given
    Started
    2024-06
    Registry
    NCT06597526

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  174. Recruiting
    ImmunoPET Imaging of Pancreatic Cancer
    Phase
    N/A
    Started
    2024-11
    Registry
    NCT06602037

    Age 18 years to 70 years (registered criteria)

    Led by Renji HospitalShanghai

  175. Recruiting
    Study of IBI363 in Patients with Advanced First-line Gastric Cancer
    Phase
    Phase 1
    Started
    2024-10
    Registry
    NCT06610799

    Age 18 years to 75 years (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  176. Recruiting
    A Phase 2 Clinical Study of ABSK061 and ABSK043
    Phase
    Phase 2
    Started
    2024-11
    Registry
    NCT06632262

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesChengdu, Guiyang, Hangzhou, Harbin, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wuhan, Xiamen, Xiangyang, Xuzhou, Zhengzhou

  177. Recruiting
    AI-Assisted Non-Contrast CT for Multi-Cancer Screening
    Phase
    N/A
    Started
    2024-10
    Registry
    NCT06632886

    Age 18 years to Not stated (registered criteria)

    Led by Changhai HospitalShanghai

  178. Recruiting
    Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ Patients
    Phase
    Phase 1/Phase 2
    Started
    2024-07
    Registry
    NCT06650332

    Age 18 years to 75 years (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  179. Recruiting
    IMmune Proteomics to Predict neoAdjuvant Chemotherapy and immunoTherapy Response in Gastric Cancer
    Phase
    Not given
    Started
    2024-08
    Registry
    NCT06662110

    Age 18 years to 75 years (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  180. Recruiting
    Application of a New Surgical Technique in Proximal Gastrectomy: a Prospective, Multicenter Randomized Controlled Study
    Phase
    N/A
    Started
    2024-12
    Registry
    NCT06679244

    Age 18 years to 80 years (registered criteria)

    Led by Huashan Hospital; 2 listed hospitals as study sitesShanghai

  181. Recruiting
    Integrative Analysis of Exosome-Mediated Single-Cell Transcriptomics and Proteomics in Gastric Cardia Cancer
    Phase
    Not given
    Started
    2024-12
    Registry
    NCT06702891

    Age 18 years to Not stated (registered criteria)

    Led by Qilu Hospital of Shandong UniversityJinan

  182. Recruiting
    Trifluridine/tipiracil (TAS-102), Bevacizumab, and Camrelizumab As Third-line or Later-line Therapy of Gastric Cancer
    Phase
    Phase 2
    Started
    2024-11
    Registry
    NCT06711471

    Age 18 years to Not stated (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  183. Recruiting
    Effect of Premedication With Pronase on Mucosal Cleanliness During EGD
    Phase
    N/A
    Started
    2024-12
    Registry
    NCT06713421

    Age 18 years to 70 years (registered criteria)

    Led by Changhai HospitalShanghai

  184. Recruiting
    Target-specific immunoPET Imaging of Digestive System Carcinoma
    Phase
    N/A
    Started
    2024-12
    Registry
    NCT06715839

    Age 18 years to 75 years (registered criteria)

    Led by Renji HospitalShanghai

  185. Recruiting
    Analysis of Lymph Node Metastasis and Tumor Deposit in the Short Gastric Mesentery Following Total Gastrectomy for Gastric Cancer
    Phase
    Not given
    Started
    2024-05
    Registry
    NCT06728878

    Age 18 years to 85 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  186. Recruiting
    Analysis of Tumor Deposit at the Fusion Site of the Right Gastric Mesentery and Left Gastric Mesentery in the Patients With Gastric Cancer Who Received Proximal Gastrectomy
    Phase
    Not given
    Started
    2024-05
    Registry
    NCT06728891

    Age 18 years to 85 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  187. Recruiting
    First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)
    Phase
    Phase 2
    Started
    2024-10
    Registry
    NCT06730373

    Age 18 years to 75 years (registered criteria)

    Led by Qilu Hospital of Shandong University; 7 listed hospitals as study sitesJinan, Linyi, Qingdao, Yantai, Zhengzhou, Zibo

  188. Recruiting
    Exploration of Lymph Node Metastasis and Tumor Deposit in the Posterior Gastric Mesentery for Distal Gastric Cancer
    Phase
    Not given
    Started
    2024-05
    Registry
    NCT06736847

    Age 18 years to 85 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  189. Recruiting
    XELOX Combined With Sintilimab and HBO for Advanced or Metastatic GC/GEJC
    Phase
    Phase 1/Phase 2
    Started
    2024-12
    Registry
    NCT06742411

    Age 18 years to 75 years (registered criteria)

    Led by West China HospitalChengdu

  190. Recruiting
    Safety and Efficacy of Traction Robot-assisted Endoscopic Submucosal Dissection for Early Gastric Cancer
    Phase
    N/A
    Started
    2024-12
    Registry
    NCT06748352

    Age 18 years to 80 years (registered criteria)

    Led by Qilu Hospital of Shandong UniversityJinan

  191. Recruiting
    MCB vs EUS-FNA for Preoperative Pathological Evaluation of Gastric SMT
    Phase
    N/A
    Started
    2024-01
    Registry
    NCT06748690

    Age 18 years to Not stated (registered criteria)

    Led by Peking University People's HospitalBeijing

  192. Recruiting
    Intraperitoneal Immune Checkpoint Inhibitors and Zoledronic Acids for Gastric Cancer Malignant Ascites
    Phase
    Phase 1/Phase 2
    Started
    2024-09
    Registry
    NCT06759064

    Age 18 years to 75 years (registered criteria)

    Led by Qilu Hospital of Shandong UniversityJinan

  193. Recruiting
    A Prospective Cohort Study on the Treatment of Locally Advanced Gastric Cancer
    Phase
    Not given
    Started
    2024-12
    Registry
    NCT06760858

    Age 18 years to 80 years (registered criteria)

    Led by Southwest Hospital, Army Medical UniversityChongqing

  194. Recruiting
    A Phase Ib/II Study of Adebrelimab in Combination with Capecitabine and Oxaliplatin in Cancer
    Phase
    Phase 1/Phase 2
    Started
    2024-08
    Registry
    NCT06776770

    Age 18 years to Not stated (registered criteria)

    Led by Cancer Hospital CAMS – ShenzhenShenzhen

  195. Recruiting
    A First-in-Human Escalation and Expansion Study of Patients With Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2024-12
    Registry
    NCT06783569

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHarbin, Shenyang

  196. Recruiting
    The Relationship of Psychological Stress With Therapy Efficacy and Prognosis of Gastric Cancer
    Phase
    Not given
    Started
    2024-09
    Registry
    NCT06786169

    Age 18 years to 80 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  197. Recruiting
    Fluorescence Guided Laparoscopic-Endoscopic Cooperative Sentinel Lymph Node Navigation Surgery Strategy for Early Gastric Cancer(IDEAL Stage 2b)
    Phase
    N/A
    Started
    2024-02
    Registry
    NCT06788548

    Age 18 years to 80 years (registered criteria)

    Led by Beijing Friendship HospitalBeijing

  198. Recruiting
    Clinical Study of Envafolimab Combined With Fruquintinib and Chemotherapy for Neoadjuvant Treatment of Gastric Cancer
    Phase
    Phase 2
    Started
    2024-06
    Registry
    NCT06791083

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Fujian Medical UniversityFuzhou

  199. Recruiting
    Low-dose Radiotherapy Combined With Chemotherapy and AK112 as Second-line Treatment in Patients With Advanced G/GEJ Cancer
    Phase
    Phase 2
    Started
    2024-07
    Registry
    NCT06791148

    Age 18 years to 75 years (registered criteria)

    Led by Nanjing Drum Tower HospitalNanjing

  200. Recruiting
    Study of CEA Targeting CAR-T (PTC13) in the Treatment of CEA-Positive Advanced Malignant Solid Tumors
    Phase
    Phase 1
    Started
    2024-07
    Registry
    NCT06821048

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  201. Recruiting
    Safety and Efficacy Study of Sorbitol With Neoadjuvant Chemotherapy Combined With Tirellizumab (PD-1 Inhibitor) in Patients With Locally Advanced Gastric Cancer
    Phase
    Phase 2
    Started
    2024-11
    Registry
    NCT06826079

    Age 18 years to 70 years (registered criteria)

    Led by Union HospitalWuhan

  202. Recruiting
    Energy CT in Imaging and Diagnosis of Gastric Cancer
    Phase
    Not given
    Started
    2024-09
    Registry
    NCT06869694

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou

  203. Recruiting
    The Safety and Efficacy of Robotic Assisted Surgery Using Vessel Sealer Extend in Locally Advanced Gastric Cancer
    Phase
    Not given
    Started
    2024-11
    Registry
    NCT06881043

    Age 18 years to 75 years (registered criteria)

    Led by First Hospital of Jilin UniversityChangchun

  204. Recruiting
    Robotic Gastrectomy for Locally Advanced Gastric Cancer After Neoadjuvant Therapy
    Phase
    Phase 2
    Started
    2024-11
    Registry
    NCT06895447

    Age 18 years to 80 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  205. Recruiting
    The Effect of Different Digestive Tract Reconstruction Methods on Postoperative Quality of Life After Proximal Gastrectomy
    Phase
    Not given
    Started
    2024-11
    Registry
    NCT06929949

    Age 18 years to 75 years (registered criteria)

    Led by First Hospital of Jilin UniversityChangchun

  206. Recruiting
    CDH17 CAR-T Therapy in Advanced Malignant Solid Tumors
    Phase
    Early phase 1
    Started
    2024-12
    Registry
    NCT06937567

    Age 18 years to 70 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  207. Recruiting
    Post-operative Monitoring of Gastric Cancer
    Phase
    Not given
    Started
    2024-02
    Registry
    NCT07026240

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  208. Recruiting
    Efficacy and Safety of Minimally Invasive D2+PAND Gastrectomy for Gastric Cancer With PAN Metastasis After Conversion Immunochemotherapy
    Phase
    N/A
    Started
    2024-11
    Registry
    NCT07056010

    Age 18 years to 80 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  209. Recruiting
    Effect of Goal-Oriented Albumin Infusion on Postoperative Complication Management in Gastric Cancer Surgery
    Phase
    Phase 2
    Started
    2024-10
    Registry
    NCT07119463

    Age 18 years to 80 years (registered criteria)

    Led by First Hospital of Jilin UniversityChangchun

  210. Recruiting
    Adebrelimab Combined With Famitinib and Irinotecan in Advanced Gastric Cancer After Failure of First-Line Therapy
    Phase
    Phase 2
    Started
    2024-07
    Registry
    NCT07309185

    Age 18 years to 75 years (registered criteria)

    Led by Shandong Cancer Hospital and InstituteJinan

  211. Recruiting
    Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric Cancer
    Phase
    Phase 1/Phase 2
    Started
    2024-02
    Registry
    NCT07334431

    Age 18 years to 75 years (registered criteria)

    Led by Henan Cancer HospitalZhengzhou

  212. Recruiting
    The Efficacy of PD-1 Monoclonal Antibody Combined With Chemotherapy in Metastatic Gastric Cancer Based on Gut Microbiota
    Phase
    Not given
    Started
    2024-03
    Registry
    NCT07400354

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  213. Recruiting
    A Long-term Follow-up Study of Subjects Enrolled in Clinical Trials of Cadonilimab (AK104)
    Phase
    Not given
    Started
    2024-12
    Registry
    NCT07547787

    Age not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  214. Recruiting
    Helicobacter Pylori Infection Status and Pathological Features for Predicting Gastric Cancer Biological Behavior and Prognosis: A Real-World Observational Study
    Phase
    Not given
    Started
    2024-01
    Registry
    NCT07724496

    Age 18 years to 80 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  215. Recruiting
    Validating a Medical AI Fine-Tuning Platform for Major Diseases
    Phase
    Not given
    Started
    2024-11
    Registry
    NCT07795645

    Age 18 years to Not stated (registered criteria)

    Led by Beijing Friendship HospitalBeijing

  216. Recruiting
    TEAS for Gastrectomy Recovery
    Phase
    N/A
    Started
    2024-10
    Registry
    NCT07898293

    Age 18 years to 80 years (registered criteria)

    Led by Affiliated Hospital of Qingdao University; 2 listed hospitals as study sitesQingdao, Weifang, Yantai

  217. Recruiting
    A Phase I Study of CG-7321 Monotherapy or Combination Therapy in Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2024-07
    Registry
    NCT07923214

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesChengdu, Fuzhou, Shanghai

  218. Recruiting
    Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab
    Phase
    Phase 1/Phase 2
    Started
    2023-02
    Registry
    NCT05319639

    Age 18 years to 75 years (registered criteria)

    Led by Fujian Cancer HospitalFuzhou

  219. Recruiting
    Transarterial Neoadjuvant Chemotherapy vs.Traditional Intravenous Chemotherapy For Locally Advanced Gastric Cancer With SOX+PD-1
    Phase
    Phase 3
    Started
    2023-03
    Registry
    NCT05593458

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  220. Recruiting
    Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer
    Phase
    Phase 2
    Started
    2023-03
    Registry
    NCT05671822

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  221. Recruiting
    Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma
    Phase
    Phase 2
    Started
    2023-03
    Registry
    NCT05687357

    Age 18 years to 75 years (registered criteria)

    Led by Nanjing Drum Tower Hospital; 2 listed hospitals as study sitesNanjing, Taiyuan, Wuhan

  222. Recruiting
    Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer
    Phase
    Phase 2/Phase 3
    Started
    2023-05
    Registry
    NCT05699655

    Age 18 years to 75 years (registered criteria)

    Led by Fujian Cancer HospitalFuzhou

  223. Recruiting
    Prediction of Peritoneal Metastasis for Gastric Cancer Based on Radiomics
    Phase
    Not given
    Started
    2023-01
    Registry
    NCT05722275

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Kunming, Taiyuan, Zhengzhou

  224. Recruiting
    Study of Comparing of With and Without Sequential Therapy of S-1
    Phase
    Phase 3
    Started
    2023-01
    Registry
    NCT05813015

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  225. Recruiting
    Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma
    Phase
    Phase 3
    Started
    2023-04
    Registry
    NCT05918094

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 7 listed hospitals as study sitesChengdu, Dalian, Guangzhou, Harbin, Nanchang, Shanghai, Wuhan, Zhengzhou

  226. Recruiting
    A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study
    Phase
    Phase 2
    Started
    2023-07
    Registry
    NCT05934331

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  227. Recruiting
    A Cohort Study on the Safety of Laparoscopic Resection of 5cm or Larger Gastric Gastrointestinal Stromal Tumors
    Phase
    Not given
    Started
    2023-05
    Registry
    NCT05938309

    Age 18 years to 75 years (registered criteria)

    Led by Fujian Medical University Union HospitalFuzhou

  228. Recruiting
    The Role of Extracellular DNA (ecDNA) in the Occurrence and Development of Gastric
    Phase
    Not given
    Started
    2023-08
    Registry
    NCT05956847

    Age 18 years to 80 years (registered criteria)

    Led by Xijing HospitalXi'an

  229. Recruiting
    Adjuvant Serplulimab and Trastuzuma and Chemotherapy in Her-2+ Gastric Cancer
    Phase
    Phase 2
    Started
    2023-01
    Registry
    NCT05975749

    Age 20 years to 80 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  230. Recruiting
    A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal Tumors
    Phase
    Phase 2
    Started
    2023-11
    Registry
    NCT06008054

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  231. Recruiting
    Phase 2 Trial of KN026+KN046±XELOX in HER2-positive Locally Advanced GC
    Phase
    Phase 2
    Started
    2023-09
    Registry
    NCT06023758

    Age 18 years to 75 years (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  232. Recruiting
    AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy
    Phase
    Not given
    Started
    2023-09
    Registry
    NCT06035250

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changsha, Fuzhou, Guangzhou, Kunming, Nanning, Qingdao, Shanghai, Shenyang, Suzhou, Tianjin, Zhengzhou

  233. Recruiting
    A Multicenter, RCT Study of the Clinical Efficacy of Robotic and Laparoscopic Gastrectomy in Neoadjuvant Gastric Cancer
    Phase
    N/A
    Started
    2023-07
    Registry
    NCT06042998

    Age 18 years to 75 years (registered criteria)

    Led by Affiliated Hospital of Qingdao UniversityQingdao

  234. Recruiting
    A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors
    Phase
    Phase 1
    Started
    2023-08
    Registry
    NCT06043466

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHangzhou

  235. Recruiting
    Neoadjuvant of Sintilimab Combined Weekly Metronomic Chemotherapy (PLOF) for Resectable Locally Advanced Gastric Cancer
    Phase
    Phase 2
    Started
    2023-10
    Registry
    NCT06054906

    Age 18 years to Not stated (registered criteria)

    Led by Huashan HospitalShanghai

  236. Recruiting
    The Efficacy and Safety of the COMBO Endoscopy Oropharyngeal Airway in Gastrointestinal Endoscopy Procedure
    Phase
    N/A
    Started
    2023-12
    Registry
    NCT06081647

    Age 18 years to 60 years (registered criteria)

    Led by Renji Hospital; 7 listed hospitals as study sitesHangzhou, Jinan, Nanchang, Nanjing, Shanghai

  237. Recruiting
    Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer
    Phase
    Phase 2
    Started
    2023-01
    Registry
    NCT06121700

    Age 18 years to 75 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  238. Recruiting
    Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes(CAR-T) for CEA Positive Advanced Malignant Solid Tumors
    Phase
    Phase 1
    Started
    2023-11
    Registry
    NCT06126406

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteWuhu

  239. Recruiting
    A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2023-11
    Registry
    NCT06131840

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Shanghai

  240. Recruiting
    Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.
    Phase
    Phase 2
    Started
    2023-11
    Registry
    NCT06155383

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Guangzhou, Harbin, Jinan, Kunming, Xiamen, Zhengzhou

  241. Recruiting
    A Study of PD-1 Inhibitors Combined With Fruquintinib and Chemotherapy in First-line Treatment of HER2-negative Advanced G/GEJ Cancer
    Phase
    N/A
    Started
    2023-11
    Registry
    NCT06158919

    Age 18 years to 80 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  242. Recruiting
    3D-4K-ICG Laparoscopic Gastrectomy for Gastric Cancer
    Phase
    Phase 3
    Started
    2023-01
    Registry
    NCT06161207

    Age 18 years to 75 years (registered criteria)

    Led by Fujian Medical University Union HospitalFuzhou

  243. Recruiting
    M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.
    Phase
    Phase 3
    Started
    2023-12
    Registry
    NCT06177041

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  244. Recruiting
    Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxans-resistant Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Gastric Cancer, Esophageal Carcinoma, or Breast Cancer
    Phase
    Phase 2
    Started
    2023-11
    Registry
    NCT06199895

    Age 18 years to Not stated (registered criteria)

    Led by Tongji HospitalWuhan

  245. Recruiting
    Atrophic Gastritis Predicts the Risk of Gastric Cancer
    Phase
    Not given
    Started
    2023-12
    Registry
    NCT06203327

    Age 18 years to 70 years (registered criteria)

    Led by Renji HospitalShanghai

  246. Recruiting
    A Study on the Safety and Efficacy of the Combination of Candenizumab, Lenvatinib, and SOX Regimen in the Treatment of HER2 Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Patients
    Phase
    N/A
    Started
    2023-01
    Registry
    NCT06277024

    Age 18 years to 75 years (registered criteria)

    Led by Fujian Medical University Union HospitalFuzhou

  247. Recruiting
    Exploratory Study of Precise Therapy for Advanced Tumor Patients With Malignant Hydrothorax or Ascites by Using PTC Drug Sensitivity Testing
    Phase
    Not given
    Started
    2023-08
    Registry
    NCT06413212

    Age 18 years to Not stated (registered criteria)

    Led by Tongji HospitalWuhan

  248. Recruiting
    a Single-arm, Single-center, Open Clinical Study
    Phase
    Not given
    Started
    2023-07
    Registry
    NCT06431100

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteZhengzhou

  249. Recruiting
    Neoadjuvant Immunotherapy Plus Chemotherapy in Borrmann Type 4 and Large Type 3 Gastric Cancer
    Phase
    Phase 2
    Started
    2023-05
    Registry
    NCT06451211

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  250. Recruiting
    A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2023-04
    Registry
    NCT06508307

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteZhengzhou

  251. Recruiting
    The Correlation Between Blood Concentration of Sintilimab and Efficacy and Adverse Reactions in Patients with Advanced Gastric Cancer
    Phase
    Not given
    Started
    2023-02
    Registry
    NCT06702683

    Age 18 years to Not stated (registered criteria)

    Led by Zhongda Hospital, Southeast UniversityNanjing

  252. Recruiting
    Study on the Value of Three DWI Scanning Sequences in Staging of Gastric Cancer
    Phase
    N/A
    Started
    2023-12
    Registry
    NCT06735105

    Age 18 years to 80 years (registered criteria)

    Led by Yunnan Cancer HospitalKunming

  253. Recruiting
    A Study of Fruquintinib Plus Chemotherapy for Postoperative Treatment of HER2-Negative Gastric Cancer With Poor TRG
    Phase
    Phase 2
    Started
    2023-09
    Registry
    NCT06774222

    Age 18 years to 75 years (registered criteria)

    Led by Henan Cancer HospitalZhengzhou

  254. Recruiting
    PD-1 Antibody Carilizumab Combined with Apatinib for Unresectable Stage III and IV DMMR Gastric Cancer
    Phase
    Phase 2
    Started
    2023-04
    Registry
    NCT06792162

    Age 18 years to Not stated (registered criteria)

    Led by Peking University Third HospitalBeijing

  255. Recruiting
    Docetaxel, Oxaliplatin and 5-FU for Gastric Cancer With Inoperable Malignant Bowel Obstruction
    Phase
    Phase 2
    Started
    2022-01
    Registry
    NCT04840264

    Age 18 years to 75 years (registered criteria)

    Led by Sixth Affiliated Hospital of Sun Yat-sen University; 1 listed hospital as study siteGuangzhou

  256. Recruiting
    A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2022-01
    Registry
    NCT05150691

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 34 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chongqing, Guangzhou, Hangzhou, Hefei, Jinan, Nanning, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wenzhou, Wuhan, Wuxi, Xi'an, Xiamen, Xuzhou, Yantai, Zhengzhou

  257. Recruiting
    A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2022-10
    Registry
    NCT05208762

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Shanghai

  258. Recruiting
    A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid Tumor
    Phase
    Phase 1
    Started
    2022-02
    Registry
    NCT05262491

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesBeijing, Chengdu, Hangzhou, Jinan, Nanchang, Tianjin

  259. Recruiting
    The Relationship Between Scar Formation and ESD Depth in Therapy for Gastric Carcinoma
    Phase
    N/A
    Started
    2022-01
    Registry
    NCT05323929

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  260. Recruiting
    Detection of Peritoneal Metastasis of Gastric Cancer by Liquid Biopsy in Peripheral Blood: A Prospective Study
    Phase
    Not given
    Started
    2022-03
    Registry
    NCT05347524

    Age 18 years to 74 years (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  261. Recruiting
    A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
    Phase
    Phase 1
    Started
    2022-06
    Registry
    NCT05365581

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesGuangzhou, Hangzhou, Shanghai, Wuhan, Zhengzhou

  262. Recruiting
    KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy
    Phase
    Phase 2/Phase 3
    Started
    2022-04
    Registry
    NCT05427383

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  263. Recruiting
    OGT-assisted Overlap Esophagojejunostomy Versus Traditional Overlap Method
    Phase
    N/A
    Started
    2022-09
    Registry
    NCT05450835

    Age 18 years to 75 years (registered criteria)

    Led by Nanfang Hospital; 7 listed hospitals as study sitesChangchun, Changsha, Guangzhou, Shantou, Shenyang

  264. Recruiting
    XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma
    Phase
    Phase 2
    Started
    2022-03
    Registry
    NCT05494060

    Age 18 years to 75 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  265. Recruiting
    Dual-Port Laparoscopic Distal Gastrectomy for Gastric Cancer
    Phase
    N/A
    Started
    2022-08
    Registry
    NCT05494086

    Age 18 years to 75 years (registered criteria)

    Led by Nanfang HospitalGuangzhou

  266. Recruiting
    The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy)
    Phase
    Phase 2
    Started
    2022-09
    Registry
    NCT05536102

    Age 18 years to 75 years (registered criteria)

    Led by Shanghai General HospitalShanghai

  267. Recruiting
    Laparoscopic vs Open Total Gastrectomy for Gastric Cancer
    Phase
    N/A
    Started
    2022-10
    Registry
    NCT05537129

    Age 20 years to 80 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  268. Recruiting
    Clinical Outcomes of Indocyanine Green Tracer Using in Laparoscopic Gastrectomy With Lymph Node Dissection for Remnant Gastric Cancer
    Phase
    Phase 2
    Started
    2022-06
    Registry
    NCT05618821

    Age 18 years to 75 years (registered criteria)

    Led by Fujian Medical University Union HospitalFuzhou

  269. Recruiting
    Treatment of Advanced Malignant Solid Tumors With Claudin18.2CAR-T
    Phase
    N/A
    Started
    2022-10
    Registry
    NCT05620732

    Age 18 years to 75 years (registered criteria)

    Led by Shenzhen University General HospitalShenzhen

  270. Recruiting
    Laparoscopic Gastrectomy With D2 Lymphadenectomy Combined With Hyperthermic Intraperitoneal Chemotherapy (HIPEC) or Not
    Phase
    Phase 3
    Started
    2022-11
    Registry
    NCT05871099

    Age 18 years to 80 years (registered criteria)

    Led by Affiliated Hospital of Qingdao UniversityQingdao

  271. Recruiting
    First-Line and Neoadjuvant Immunotherapy for Gastric Cancer
    Phase
    Not given
    Started
    2022-01
    Registry
    NCT06727981

    Age 18 years to 100 years (registered criteria)

    Led by Qilu Hospital of Shandong UniversityJinan

  272. Recruiting
    Raman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early Diagnosis
    Phase
    Not given
    Started
    2022-09
    Registry
    NCT06822413

    Age not stated (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang University; 3 listed hospitals as study sitesHangzhou, Nanchang, Shanghai

  273. Recruiting
    Oxaliplatin Combined With S-1(SOX) Neoadjuvant Chemotherapy for Different Cycles in Patients With Gastric Cancer
    Phase
    Phase 3
    Started
    2021-01
    Registry
    NCT04483076

    Age 18 years to 70 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  274. Recruiting
    Multicenter Study on Laparoscopic Total Gastrectomy for Advanced Gastric Cancer
    Phase
    N/A
    Started
    2021-01
    Registry
    NCT04710758

    Age 18 years to 75 years (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  275. Recruiting
    Comparation of Endoscopic Biopsy and Postoperative Specimen for the Molecular Diagnosis of Gastric Cancer
    Phase
    Not given
    Started
    2021-05
    Registry
    NCT04809025

    Age 18 years to 75 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  276. Recruiting
    A Phase III Study Comparing Total and Partial Omentectomy for Patients With Advanced Gastric Cancer
    Phase
    N/A
    Started
    2021-01
    Registry
    NCT04843215

    Age 18 years to 70 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  277. Recruiting
    Relationship Between Perioperative Treatment Efficacy and The Tumor Microenvironment for Locally Advanced Resectable Gastric Cancer.
    Phase
    Not given
    Started
    2021-05
    Registry
    NCT04850729

    Age 18 years to 75 years (registered criteria)

    Led by Nanfang HospitalGuangzhou

  278. Recruiting
    Toripalimab Plus FLOT in Locally Advanced Gastric Cancer
    Phase
    Phase 2
    Started
    2021-06
    Registry
    NCT04891016

    Age 18 years to 70 years (registered criteria)

    Led by Henan Cancer HospitalZhengzhou

  279. Recruiting
    Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
    Phase
    Phase 1
    Started
    2021-06
    Registry
    NCT04900818

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Harbin, Hefei, Shanghai, Shenyang, Tianjin, Wuhan, Zhengzhou

  280. Recruiting
    Study of Adjuvant Chemotherapy With or Without PD-1 Inhibitors and Chemoradiotherapy in Resected pN3 Gastric (G) or GEJ Adenocarcinoma
    Phase
    Phase 3
    Started
    2021-07
    Registry
    NCT04997837

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  281. Recruiting
    Gastric Cancer Marker Detection and Its Kit Development
    Phase
    Not given
    Started
    2021-01
    Registry
    NCT05010863

    Age not stated (registered criteria)

    Led by Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical UniversityWenzhou

  282. Recruiting
    PD-1 Blockade With JS001 Plus Neoadjuvant Chemotherapy for Gastric/Gastroesophageal Junction Cancer
    Phase
    Phase 2
    Started
    2021-09
    Registry
    NCT05033392

    Age 18 years to 79 years (registered criteria)

    Led by Shenzhen People's HospitalShenzhen

  283. Recruiting
    Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2021-11
    Registry
    NCT05187338

    Age 18 years to 70 years (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  284. Recruiting
    Multi-parametric MRI and Dual-energy CT in Patients of Gastric Cancer
    Phase
    Not given
    Started
    2021-11
    Registry
    NCT05508126

    Age 18 years to Not stated (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  285. Recruiting
    Proximal Gastrectomy Anterior Anastomosis With Pyloroplasty Versus Esophagogastric Anastomosis for Gastric Cancer
    Phase
    N/A
    Started
    2021-01
    Registry
    NCT05514769

    Age 18 years to 85 years (registered criteria)

    Led by Nanchong Central HospitalNanchong

  286. Recruiting
    Development of Novel Gastric Cancer Screening and Diagnosis Technologies Using Tongue Imaging and Study of Tongue Image Changes Mechanisms
    Phase
    Not given
    Started
    2021-06
    Registry
    NCT06078930

    Age 18 years to 90 years (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  287. Recruiting
    Carilizumab and Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer
    Phase
    Phase 2
    Started
    2021-03
    Registry
    NCT07320586

    Age 18 years to 75 years (registered criteria)

    Led by Shandong Cancer Hospital and InstituteJinan

  288. Recruiting
    Samples Procurement for Colorectal Cancer, Gastric Cancer, and Non-malignant Disease
    Phase
    Not given
    Started
    2020-12
    Registry
    NCT03972956

    Age 18 years to 80 years (registered criteria)

    Led by Renmin Hospital of Wuhan UniversityWuhan

  289. Recruiting
    Reduced Port Laparoscopic Gastrectomy for Gastric Cancer
    Phase
    N/A
    Started
    2020-03
    Registry
    NCT04295473

    Age 18 years to 90 years (registered criteria)

    Led by Nanchong Central HospitalNanchong

  290. Recruiting
    Ajuvant Chemotherapy and Immunotherapy in Patients With Esophageal, Esophageal- Gastric Junction Cancer
    Phase
    N/A
    Started
    2020-07
    Registry
    NCT04688801

    Age 25 years to 80 years (registered criteria)

    Led by Second Hospital of Shandong UniversityJinan

  291. Recruiting
    Prediction of Neoadjuvant Chemotherapy Efficacy in Locally Advanced Gastric Cancer
    Phase
    N/A
    Started
    2020-09
    Registry
    NCT05140746

    Age 18 years to 75 years (registered criteria)

    Led by Ruijin HospitalShanghai

  292. Recruiting
    Linear Stapler Versus Circular Stapler in Esophagojejunostomy
    Phase
    N/A
    Started
    2020-01
    Registry
    NCT05360069

    Age 18 years to 90 years (registered criteria)

    Led by Nanchong Central HospitalNanchong

  293. Recruiting
    S-1 for 9 Months Versus 1 Year for Stage II Gastric Cancer (SMAC)
    Phase
    Phase 3
    Started
    2019-01
    Registry
    NCT03941561

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesHefei, Nanchang, Wuhu

  294. Recruiting
    Paclitaxel (Albumin-bound) Combined With Oxaliplatin and S-1 Conversion Therapy for Gastric Adenocarcinoma
    Phase
    N/A
    Started
    2019-09
    Registry
    NCT04047953

    Age 18 years to 75 years (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  295. Recruiting
    Comparison of Tumor Efficacy Safety in Laparoscopic Resection of Gastrointestinal Stromal Tumors Between Favorable and Unfavorable Site
    Phase
    Not given
    Started
    2018-10
    Registry
    NCT03716089

    Age 18 years to 75 years (registered criteria)

    Led by Fujian Medical University Union HospitalFuzhou

  296. Recruiting
    Apatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric Cancer
    Phase
    Phase 2
    Started
    2017-09
    Registry
    NCT03219593

    Age 65 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Bengbu Medical UniversityBengbu

  297. Recruiting
    Predicting Gastric Cancer Response to Chemo With Multimodal AI Model
    Phase
    Not given
    Started
    2013-02
    Registry
    NCT06451393

    Age 20 years to 90 years (registered criteria)

    Led by Sixth Affiliated Hospital of Sun Yat-sen UniversityGuangzhou

  298. Not yet recruiting
    Sintilimab Plus FOLFIRI as Second-line Therapy for Patients With HER2-negative Advanced Gastric Cancer
    Phase
    Phase 2
    Started
    2026-06
    Registry
    NCT06365008

    Age 18 years to Not stated (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  299. Not yet recruiting
    Esomeprazole Plus Sucralfate for Post-ESD Ulcer Healing
    Phase
    Phase 4
    Started
    2026-04
    Registry
    NCT07312370

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteLanzhou

  300. Not yet recruiting
    Clinical Efficacy of Adebrelimab With or Without Apatinib Mesilate and SOX Neoadjuvant Therapy in Locally Advanced Gastric Cancer
    Phase
    Phase 3
    Started
    2026-12
    Registry
    NCT07314203

    Age 18 years to 75 years (registered criteria)

    Led by Fujian Medical University Union HospitalFuzhou

  301. Not yet recruiting
    Recurrence After Gastric and Intestinal Polyp Resection
    Phase
    Not given
    Started
    2026-07
    Registry
    NCT07314554

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteLanzhou

  302. Not yet recruiting
    QL1706-SOX vs SOX Alone as Neoadjuvant Therapy for Resectable Diffuse-Type Gastric Cancer
    Phase
    Phase 2
    Started
    2026-01
    Registry
    NCT07315035

    Age 18 years to 75 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  303. Not yet recruiting
    Robotic vs Laparoscopic Gastrectomy for cT4a Gastric Cancer
    Phase
    Phase 3
    Started
    2026-02
    Registry
    NCT07331454

    Age 18 years to 75 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  304. Not yet recruiting
    A Hypoxia-Inducible CAR-T Cell Targeting AXL and CD73 for Advanced Gastric Cancer
    Phase
    Phase 1/Phase 2
    Started
    2026-01
    Registry
    NCT07333573

    Age 18 years to 75 years (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  305. Not yet recruiting
    IBI363 Plus Bevacizumab With or Without Nab-Paclitaxel for Second-Line Treatment of Advanced Gastric Cancer
    Phase
    Phase 1/Phase 2
    Started
    2026-03
    Registry
    NCT07361991

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou

  306. Not yet recruiting
    Perioperative Ivonescimab Plus S-1 and Oxaliplatin (SOX) for Locally Advanced Gastric or GEJ Adenocarcinoma
    Phase
    Phase 2
    Started
    2026-02
    Registry
    NCT07374250

    Age 18 years to 75 years (registered criteria)

    Led by West China HospitalChengdu

  307. Not yet recruiting
    Megestrol Acetate Oral Suspension for Cachexia in Patients With cStage III Gastric/Gastroesophageal Junction Adenocarcinoma Receiving Neoadjuvant Therapy With Serplulimab Combined With SOX
    Phase
    Phase 2
    Started
    2026-02
    Registry
    NCT07391826

    Age 18 years to 80 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  308. Not yet recruiting
    Clinical Study of CBG131 CAR-T Cell Injection for the Treatment of CLDN18.2-Positive Advanced Gastric and Pancreatic Cancer
    Phase
    Early phase 1
    Started
    2026-09
    Registry
    NCT07394205

    Age 18 years to 70 years (registered criteria)

    Led by First Affiliated Hospital of Wenzhou Medical UniversityWenzhou

  309. Not yet recruiting
    LDRT Sequential NIPS Immunochemotherapy for Peritoneal Metastasis of Gastric and Colorectal Cancer
    Phase
    Phase 1
    Started
    2026-05
    Registry
    NCT07453875

    Age 18 years to 75 years (registered criteria)

    Led by Daping Hospital, Army Medical UniversityChongqing

  310. Not yet recruiting
    Evaluation of Pressurized Intraperitoneal Aerosol Chemotherapy With VRT106 Versus PIPAC in Patients With Advanced Gastric Cancer and PeritonealMetastasis: A Prospective, Multicenter, Open-Label, Randomized Controlled Trial
    Phase
    Phase 2
    Started
    2026-03
    Registry
    NCT07486310

    Age 18 years to 75 years (registered criteria)

    Led by Guangdong Provincial People's HospitalGuangzhou

  311. Not yet recruiting
    Comparison of the Sensitivity of pCLE and Pathological Biopsy for Gastric Mucosal Lesions
    Phase
    Not given
    Started
    2026-03
    Registry
    NCT07507071

    Age 18 years to 75 years (registered criteria)

    Led by Changhai HospitalShanghai

  312. Not yet recruiting
    A Study of Disitamab Vedotin, Tunlametinib, and PD-1 Antibody for Advanced Gastric Cancer
    Phase
    Phase 2
    Started
    2026-04
    Registry
    NCT07507526

    Age 18 years to Not stated (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  313. Not yet recruiting
    Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric Cancer With Neoadjuvant Treatment
    Phase
    Phase 3
    Started
    2026-06
    Registry
    NCT07508956

    Age 18 years to Not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  314. Not yet recruiting
    18F-FAPI PET/CT and MRI in Gastric Cancer
    Phase
    Not given
    Started
    2026-05
    Registry
    NCT07510867

    Age 20 years to 80 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  315. Not yet recruiting
    Beta-Blockers on the Efficacy of Neoadjuvant Immunotherapy for Gastric Cancer
    Phase
    Phase 2
    Started
    2026-05
    Registry
    NCT07511894

    Age 18 years to 75 years (registered criteria)

    Led by Nanfang HospitalGuangzhou

  316. Not yet recruiting
    Non-Invasive Detection of claudin18.2 in Pancreatic and Gastric/Gastroesophageal Junction Cancer by [68Ga]Ga-NODAGA-SNA014 PET Imaging
    Phase
    Not given
    Started
    2026-04
    Registry
    NCT07554742

    Age 18 years to 75 years (registered criteria)

    Led by Ruijin HospitalShanghai

  317. Not yet recruiting
    Stomach-Partitioning Versus Conventional Gastrojejunostomy for Malignant Gastric Outlet Obstruction: A Multicenter Randomized Controlled Trial
    Phase
    N/A
    Started
    2026-10
    Registry
    NCT07561073

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteNanning

  318. Not yet recruiting
    Adaptive Adjuvant Therapy After Neoadjuvant Therapy and Gastrectomy for Gastric or Gastroesophageal Junction Adenocarcinoma
    Phase
    Phase 2/Phase 3
    Started
    2026-06
    Registry
    NCT07603349

    Age 18 years to 75 years (registered criteria)

    Led by Nanfang HospitalGuangzhou

  319. Not yet recruiting
    Retlirafusp Alfa Combined With Apatinib and Nab-Paclitaxel as Second-line Treatment for Gastric or Gastroesophageal Junction Cancer
    Phase
    Phase 2
    Started
    2026-05
    Registry
    NCT07610629

    Age 18 years to Not stated (registered criteria)

    Led by Henan Cancer HospitalZhengzhou

  320. Not yet recruiting
    A Study on the Efficacy of Sodium Propionate Combined With Anti-PD-1 Immunotherapy in Gastric Cancer
    Phase
    N/A
    Started
    2026-05
    Registry
    NCT07615907

    Age 18 years to 80 years (registered criteria)

    Led by Jinling HospitalNanjing

  321. Not yet recruiting
    Tafolecimab Combined With Sintilimab and SOX in the Treatment of pMMR/MSS Gastric Cancer
    Phase
    Phase 2
    Started
    2026-06
    Registry
    NCT07621562

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  322. Not yet recruiting
    Mannatide Combined With CAPOX and Tislelizumab for Advanced Gastric Cancer.
    Phase
    Phase 2
    Started
    2026-07
    Registry
    NCT07655661

    Age 18 years to 75 years (registered criteria)

    Led by West China HospitalChengdu

  323. Not yet recruiting
    Non-Operative Management and Following Immunotherapy for Colorectal Cancer and Other GI Cancers
    Phase
    Not given
    Started
    2026-06
    Registry
    NCT07656740

    Age not stated (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  324. Not yet recruiting
    One-Click Autofocus Versus Segmented Focus in Gastric Endoscopy
    Phase
    N/A
    Started
    2026-06
    Registry
    NCT07664813

    Age 18 years to Not stated (registered criteria)

    Led by Qilu Hospital of Shandong UniversityJinan

  325. Not yet recruiting
    A Study on the Efficacy and Safety of Sintilimab Combined With Ramucirumab and Paclitaxel in the Treatment of Gastric Cancer Patients With Short-term Recurrence After Adjuvant Therapy
    Phase
    Phase 2
    Started
    2026-07
    Registry
    NCT07669740

    Age 15 years to 75 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  326. Not yet recruiting
    Zanidatamab Combined With Chemotherapy as Neoadjuvant/Conversion Therapy for HER2-Positive (IHC 3+ or IHC 2+) Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a Phase II Open-Label Study
    Phase
    Phase 2
    Started
    2026-07
    Registry
    NCT07685704

    Age 18 years to 75 years (registered criteria)

    Led by Xijing HospitalXi'an

  327. Not yet recruiting
    Sacituzumab Tirumotecan (Sac-TMT/SKB264) Plus Tagitanlimab (KL-A167) in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma
    Phase
    Phase 2
    Started
    2026-08
    Registry
    NCT07701681

    Age 18 years to Not stated (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  328. Not yet recruiting
    Prospective Assessment of Alignment Between Multimodal Artificial Intelligence and Multidisciplinary Team Decisions in Gastrointestinal Oncology
    Phase
    Not given
    Started
    2026-08
    Registry
    NCT07746830

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  329. Not yet recruiting
    Home-based Whole Course Multimodal Prehabilitation Based on 5G + Artificial Intelligence Mobile Health
    Phase
    N/A
    Started
    2026-08
    Registry
    NCT07764523

    Age 18 years to Not stated (registered criteria)

    Led by Affiliated Hospital of Qingdao UniversityQingdao

  330. Not yet recruiting
    AI-Assisted Novel rbcDNA Detection for Early Gastric Cancer Diagnosis
    Phase
    Not given
    Started
    2026-09
    Registry
    NCT07782294

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang University; 2 listed hospitals as study sitesAnyang, Hangzhou, Shanghai

  331. Not yet recruiting
    A Sequential Trial of Low-Dose Radiotherapy Followed by Concurrent Immunotherapy, Systemic Chemotherapy, and Intraperitoneal Perfusion in Gastric Cancer With Peritoneal Carcinomatosis
    Phase
    Phase 2
    Started
    2026-09
    Registry
    NCT07784413

    Age 18 years to Not stated (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  332. Not yet recruiting
    High-Flow Nasal Cannula Oxygenation During Sedated Gastrointestinal Endoscopy in Patients With Chronic Obstructive Pulmonary Disease
    Phase
    N/A
    Started
    2026-08
    Registry
    NCT07791979

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  333. Not yet recruiting
    TR115 in ARID1A-Mutated Advanced Solid Tumors
    Phase
    Phase 2
    Started
    2026-09
    Registry
    NCT07793318

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  334. Not yet recruiting
    ctDNA-MRD Monitoring After Neoadjuvant Therapy in Gastric Cancer With pCR or MPR
    Phase
    Not given
    Started
    2026-09
    Registry
    NCT07799649

    Age 18 years to 75 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  335. Not yet recruiting
    Safety and Efficacy Evaluation of Single-Port Versus Multi-Port Robotic-Assisted Radical Distal Gastrectomy for Gastric Cancer
    Phase
    N/A
    Started
    2026-10
    Registry
    NCT07828899

    Age 18 years to 85 years (registered criteria)

    Led by First Affiliated Hospital of Wenzhou Medical University; 2 listed hospitals as study sitesJinan, Shijiazhuang, Wenzhou

  336. Not yet recruiting
    Exploring the Efficacy of Ferrous Sulfate/Ferrous Succinate Combined With Serplulimab and SOX Regimen in Neoadjuvant Therapy for Gastric Cancer: A Prospective Cohort Study
    Phase
    Phase 2
    Started
    2026-09
    Registry
    NCT07872696

    Age 18 years to 75 years (registered criteria)

    Led by Union HospitalWuhan

  337. Not yet recruiting
    A Phase II Study of Ipilimumab N01 Plus Sintilimab for MSI-H or dMMR Gastric and Gastroesophageal Junction Cancer
    Phase
    Phase 2
    Started
    2026-10
    Registry
    NCT07878221

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  338. Not yet recruiting
    Multimodal Liquid-Biopsy Omics Biomarkers of Treatment Response in Breast Cancer
    Phase
    Not given
    Started
    2026-10
    Registry
    NCT07880106

    Age 18 years to 80 years (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  339. Not yet recruiting
    Lymph Node Dissection After Neoadjuvant Therapy for Gastric and EGJ Adenocarcinoma
    Phase
    Not given
    Started
    2026-10
    Registry
    NCT07902596

    Age 18 years to Not stated (registered criteria)

    Led by Jiangsu Province Hospital; 6 listed hospitals as study sitesNanjing, Qingdao, Shanghai, Shijiazhuang, Suzhou

  340. Not yet recruiting
    SND002 Cell Injection in Participants With Advanced Malignant Solid Tumors
    Phase
    Phase 1
    Started
    2026-12
    Registry
    NCT07903857

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteHangzhou

  341. Not yet recruiting
    Effect of High-flow Nasal Cannula Oxygenation on the Incidence of Hypoxemia During Painless Gastrointestinal Endoscopy in Patients at High Risk for Obstructive Sleep Apnea Syndrome in High-altitude Regions
    Phase
    N/A
    Started
    2026-11
    Registry
    NCT07904260

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteHangzhou

  342. Not yet recruiting
    D2 Gastrectomy With or Without Para-Aortic Lymph Node Dissection After Chemoimmunotherapy for Gastric Cancer
    Phase
    Phase 2
    Started
    2026-11
    Registry
    NCT07912606

    Age 18 years to 75 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  343. Not yet recruiting
    Neoadjuvant SHR-A1811 ± Adebrelimab in GC/GEJ
    Phase
    Phase 2
    Started
    2026-11
    Registry
    NCT07912957

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  344. Not yet recruiting
    Multi-center Prospective Validation of Real-Time AI-EGGIM System
    Phase
    Not given
    Started
    2026-11
    Registry
    NCT07915843

    Age not stated (registered criteria)

    Led by Qilu Hospital of Shandong UniversityJinan

  345. Not yet recruiting
    GK01 Cell Therapy in Gastric Cancer With Peritoneal Metastasis
    Phase
    Phase 1
    Started
    2026-11
    Registry
    NCT07923396

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  346. Not yet recruiting
    A Real-World Study of Neoadjuvant/Conversion Therapy for Locally Advanced or Metastatic Gastric Cancer
    Phase
    Not given
    Started
    2025-04
    Registry
    NCT06464601

    Age 18 years to 75 years (registered criteria)

    Led by Zhongnan Hospital of Wuhan UniversityWuhan

  347. Not yet recruiting
    Preliminary Efficacy Analysis of "C" Single Flap Plasty Reconstruction After Laparoscopic Proximal Gastrectomy
    Phase
    N/A
    Started
    2025-01
    Registry
    NCT06741501

    Age 18 years to 80 years (registered criteria)

    Led by Northern Jiangsu People's HospitalYangzhou

  348. Not yet recruiting
    Endoscopic Cryoablation Combined With PD-1 in Advanced Gastric Cancer
    Phase
    Phase 2
    Started
    2025-05
    Registry
    NCT06759233

    Age 18 years to 80 years (registered criteria)

    Led by Huashan HospitalShanghai

  349. Not yet recruiting
    Predicting Gastric Neoplasia in Patients with High-risk Endoscopic Features
    Phase
    Not given
    Started
    2025-03
    Registry
    NCT06853509

    Age 45 years to Not stated (registered criteria)

    Led by Huadong Hospital, Fudan UniversityShanghai

  350. Not yet recruiting
    Fruquintinib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advanced Gastric Cancer
    Phase
    Phase 1/Phase 2
    Started
    2025-03
    Registry
    NCT06871527

    Age 18 years to 75 years (registered criteria)

    Led by Sixth Affiliated Hospital of Sun Yat-sen UniversityGuangzhou

  351. Not yet recruiting
    Fruquintinib Combined With PD-1 Inhibitor as First-line Maintenance Therapy for Advanced Gastric Cancer
    Phase
    Phase 2
    Started
    2025-03
    Registry
    NCT06888037

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  352. Not yet recruiting
    A Study of Disitamab Vedotin Combined With Tislelizumab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in HER2-Low Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
    Phase
    Phase 3
    Started
    2025-05
    Registry
    NCT06944496

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  353. Not yet recruiting
    A Randomized Controlled Study of Endoscopic Cryoablation Combined With PD-1 Inhibitor for Maintenance Therapy in Advanced Gastric Cancer
    Phase
    Phase 2
    Started
    2025-05
    Registry
    NCT06957977

    Age 18 years to Not stated (registered criteria)

    Led by Huashan HospitalShanghai

  354. Not yet recruiting
    The Application Value of Spectral CT in the Accurate Staging of Gastric Cancer
    Phase
    N/A
    Started
    2025-06
    Registry
    NCT06977386

    Age 18 years to 80 years (registered criteria)

    Led by Yunnan Cancer HospitalKunming

  355. Not yet recruiting
    Node-Sparing Short-Course Radiotherapy Plus First-Line Therapy and PD-1 Inhibitor in Unresectable/Metastastic pMMR/MSS Gastric Cancer (MODIFI-GC)
    Phase
    Phase 2
    Started
    2025-05
    Registry
    NCT06980389

    Age 18 years to 75 years (registered criteria)

    Led by Sixth Affiliated Hospital of Sun Yat-sen UniversityGuangzhou

  356. Not yet recruiting
    Therapeutic Study of 177Lu-CTR-FAPI in Advanced Metastatic Digestive Malignancies
    Phase
    N/A
    Started
    2025-06
    Registry
    NCT07014254

    Age 18 years to 80 years (registered criteria)

    Led by Xijing HospitalXi'an

  357. Not yet recruiting
    Neoadjuvant Nab-Paclitaxel Plus Oxaliplatin, S-1, and Sintilimab in Early-Onset Resectable Gastric Cancer
    Phase
    Phase 2
    Started
    2025-10
    Registry
    NCT07018063

    Age 16 years to 45 years (registered criteria)

    Led by Peking University People's HospitalBeijing

  358. Not yet recruiting
    PD-1-M1-NK Cells in the Treatment of Advanced Gastric or Colorectal Cancer
    Phase
    Phase 1
    Started
    2025-06
    Registry
    NCT07031011

    Age 18 years to 75 years (registered criteria)

    Led by First Hospital of Jilin UniversityChangchun

  359. Not yet recruiting
    A Clinical Trail of KJ015 in Patients With HER2-Expressing Solid Tumors
    Phase
    Phase 1
    Started
    2025-06
    Registry
    NCT07036185

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  360. Not yet recruiting
    Omega-3 Supplementation and Immunotherapy in Gastric Cancer: A Phase II Trial
    Phase
    Phase 2
    Started
    2025-09
    Registry
    NCT07050524

    Age 18 years to 80 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  361. Not yet recruiting
    Perioperative Tislelizumab Plus Chemotherapy Versus Chemotherapy Alone in MHC-II-Positive Gastric/GEJ Cancer
    Phase
    Phase 3
    Started
    2025-07
    Registry
    NCT07068516

    Age 18 years to 80 years (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  362. Not yet recruiting
    Comparison of the Sensitivity of pCLE and Pathological Biopsy Before ESD
    Phase
    Not given
    Started
    2025-07
    Registry
    NCT07088744

    Age 18 years to 80 years (registered criteria)

    Led by Changhai Hospital; 1 listed hospital as study siteChengdu, Shanghai

  363. Not yet recruiting
    Acupuncture Combined With Chemotherapy for Gastric Cancer After Surgery
    Phase
    N/A
    Started
    2025-08
    Registry
    NCT07098949

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesGuangzhou

  364. Not yet recruiting
    The Efficacy and Safety of Iparomlimab/Tuvonralimab (Anti PD-1/CTLA-4) Combined With Albumin-bound Paclitaxel in Second-line Treatment of Patients With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
    Phase
    N/A
    Started
    2025-09
    Registry
    NCT07139587

    Age 18 years to 75 years (registered criteria)

    Led by Hebei General HospitalShijiazhuang

  365. Not yet recruiting
    Clinical Application of PET Imaging Targeting GPA33 in Malignant Tumors
    Phase
    N/A
    Started
    2025-10
    Registry
    NCT07172503

    Age 18 years to 70 years (registered criteria)

    Led by Union HospitalWuhan

  366. Not yet recruiting
    Family-Supervised Prehabilitation to Reduce Postoperative Complications After Neoadjuvant Chemotherapy in Gastric Cancer
    Phase
    N/A
    Started
    2025-09
    Registry
    NCT07183358

    Age 18 years to 80 years (registered criteria)

    Led by Affiliated Hospital of Qingdao UniversityQingdao

  367. Not yet recruiting
    A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers
    Phase
    Phase 2
    Started
    2025-11
    Registry
    NCT07233850

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteWuhan

  368. Not yet recruiting
    Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric Cancer With Neoadjuvant Treatment: An Adaptive Trial (MRD-ATLAS)
    Phase
    Phase 2
    Started
    2025-12
    Registry
    NCT07257380

    Age 18 years to 79 years (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  369. Not yet recruiting
    Novel Humanized Ferritin-based NIR Fluorescent Molecular Probe for Identifying Tumor Margins in Gastric Tissue
    Phase
    Not given
    Started
    2025-12
    Registry
    NCT07276854

    Age 18 years to Not stated (registered criteria)

    Led by Nanfang HospitalGuangzhou

  370. Not yet recruiting
    A Prospective, Phase II Clinical Study of HIPEC Combined With NIPS and Tislelizumab Conversion Therapy for Gastric Cancer With Peritoneal Metastasis With Positive Cytology Alone or PCI Score ≤10
    Phase
    Phase 2
    Started
    2025-12
    Registry
    NCT07304258

    Age 18 years to 75 years (registered criteria)

    Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang

  371. Not yet recruiting
    Effect and Safety of Huaier Granule Versus SOX Regimen in Gastric Cancer Patients
    Phase
    Phase 4
    Started
    2024-07
    Registry
    NCT05498766

    Age 18 years to 75 years (registered criteria)

    Led by Union Hospital; 1 listed hospital as study siteQingdao, Wuhan

  372. Not yet recruiting
    Efficacy and Safety of Sintilimab Combined With Nab-paclitaxel and Tegio (aTS) as First-line Treatment of Unresectable Locally Advanced, Recurrent or Metastatic Adenocarcinoma of Gastric and Gastroesophageal Junction,a Phase II Clinical Study
    Phase
    Phase 2
    Started
    2024-02
    Registry
    NCT06241469

    Age 18 years to 80 years (registered criteria)

    Led by Third Affiliated Hospital of Soochow UniversityChangzhou

  373. Not yet recruiting
    Neoadjuvant Cadonilimab Plus Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial
    Phase
    Phase 2
    Started
    2024-03
    Registry
    NCT06310473

    Age 18 years to 75 years (registered criteria)

    Led by Nanfang HospitalGuangzhou

  374. Not yet recruiting
    Tislelizumab Combined With Neoadjuvant Chemotherapy Used in the Perioperative Treatment.
    Phase
    Phase 2
    Started
    2024-04
    Registry
    NCT06374901

    Age 18 years to 75 years (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  375. Not yet recruiting
    Evaluation of the Efficacy and Safety of Indocyanine Green Tracing in 3D Fluorescent Laparoscopic Lymph Node Dissection for Gastric Cancer
    Phase
    N/A
    Started
    2024-05
    Registry
    NCT06421220

    Age 18 years to 75 years (registered criteria)

    Led by Qilu Hospital of Shandong UniversityJinan

  376. Not yet recruiting
    Conversion Therapy of Sintilimab in Combination With Fruquintinib and Chemotherapy Versus Sintilimab and Chemotherpay in Stage IV Gastric Cancer
    Phase
    Phase 2
    Started
    2024-06
    Registry
    NCT06454435

    Age 18 years to 70 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  377. Not yet recruiting
    RC48 Plus AK104 as First-line Treatment for HER2-overexpressing Advanced Gastric Cancer
    Phase
    Phase 2
    Started
    2024-07
    Registry
    NCT06492317

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou

  378. Not yet recruiting
    Prospective Observational Cohort Study
    Phase
    Not given
    Started
    2024-07
    Registry
    NCT06493448

    Age 18 years to Not stated (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  379. Not yet recruiting
    A Real-world Research on the Prevention and Treatment of Peritoneal Metastasis and Malignant Ascites by Intraperitoneal Infusion of rmhTNF in Gastric and Colorectal Malignant Tumors
    Phase
    Not given
    Started
    2024-08
    Registry
    NCT06496919

    Age 18 years to 80 years (registered criteria)

    Led by Zhongnan Hospital of Wuhan UniversityWuhan

  380. Not yet recruiting
    Clinical Study of Irinotecan Liposome Combination Therapy for Advanced Gastric Cancer
    Phase
    Phase 4
    Started
    2024-07
    Registry
    NCT06499610

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Xi'an Jiaotong UniversityXi'an

  381. Not yet recruiting
    Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation
    Phase
    Phase 2
    Started
    2024-08
    Registry
    NCT06531291

    Age 18 years to 75 years (registered criteria)

    Led by Renji HospitalShanghai

  382. Not yet recruiting
    A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway
    Phase
    Phase 1
    Started
    2024-11
    Registry
    NCT06614751

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing

  383. Not yet recruiting
    SHR-A1811 Combined with Apatinib in the Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer
    Phase
    Phase 2
    Started
    2024-12
    Registry
    NCT06666166

    Age 18 years to 75 years (registered criteria)

    Led by First Hospital of China Medical UniversityShenyang

  384. Not yet recruiting
    Comparing the Efficacy of Sintilimab Plus Nab-POF Regimen, Sintilimab Plus XELOX Chemotherapy, and Lenvatinib, Sintilimab Plus XELOX Chemotherapy in the Treatment of HER2-negative, Metastatic Gastric Cancer
    Phase
    Phase 2
    Started
    2024-12
    Registry
    NCT06748508

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  385. Not yet recruiting
    Laparoscopic Proximal Gastrectomy With Double-flap Technique Versus Laparoscopic Total Gastrectomy With Roux-en-Y Reconstruction for Proximal Early Gastric Cancer
    Phase
    N/A
    Started
    2023-06
    Registry
    NCT05890339

    Age 20 years to 80 years (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  386. Not yet recruiting
    Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma
    Phase
    Phase 2
    Started
    2023-07
    Registry
    NCT05970627

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesHangzhou, Ningbo

  387. Not yet recruiting
    the Clinical Efficacy of Robotic and Laparoscopic Radical Total Gastrectomy in Locally Advanced Middle and Upper Gastric Cancer
    Phase
    N/A
    Started
    2022-02
    Registry
    NCT05235932

    Age 18 years to 75 years (registered criteria)

    Led by Fujian Medical University Union HospitalFuzhou

  388. Not yet recruiting
    The Safe Study of Routine Closure of Mesenteric Defects Versus Non-closure After Radical Gastrectomy
    Phase
    N/A
    Started
    2022-04
    Registry
    NCT05356156

    Age 18 years to 75 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  389. Not yet recruiting
    Clinical Study of Camrelizumab, Apatinib Mesylate and Nab-paclitaxel Combined With Oxplatin and S-1 in the Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Genotypes
    Phase
    Phase 2
    Started
    2022-09
    Registry
    NCT05524974

    Age 18 years to 75 years (registered criteria)

    Led by Fujian Medical University Union HospitalFuzhou

  390. Not yet recruiting
    Clinical Efficacy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Immunotypes
    Phase
    Phase 3
    Started
    2022-11
    Registry
    NCT05610332

    Age 18 years to 75 years (registered criteria)

    Led by Fujian Medical University Union HospitalFuzhou

  391. Not yet recruiting
    Dragon III-Phase 3: Neoadjuvant Chemotherapy (FLOT Versus SOX) for Gastric Cancer
    Phase
    Phase 3
    Started
    2021-09
    Registry
    NCT04384601

    Age 18 years to 80 years (registered criteria)

    Led by Ruijin HospitalShanghai

  392. Not yet recruiting
    Total Robotic Versus Robotic Assisted Distal Gastrectomy for Gastric Cancer
    Phase
    N/A
    Started
    2021-03
    Registry
    NCT04795063

    Age 18 years to 75 years (registered criteria)

    Led by Fujian Medical University Union HospitalFuzhou

  393. Not yet recruiting
    Endoscopic Submucosal Dissection Versus Surgery in the Treatment of Early Gastric Cancer
    Phase
    N/A
    Started
    2019-03
    Registry
    NCT03857737

    Age not stated (registered criteria)

    Led by Peking University Third HospitalBeijing

  394. Enrolling by invitation
    Early Postoperative Intervention in Gastric Cancer Patients
    Phase
    N/A
    Started
    2026-02
    Registry
    NCT07444099

    Age 18 years to 80 years (registered criteria)

    Led by Qilu Hospital of Shandong UniversityJinan

  395. Enrolling by invitation
    Anemia on Sublingual Microcirculation in GDFT
    Phase
    Not given
    Started
    2026-05
    Registry
    NCT07583927

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  396. Enrolling by invitation
    Non-surgical Management After NIT for dMMR/MSI-H GC
    Phase
    Not given
    Started
    2026-07
    Registry
    NCT07646574

    Age 18 years to Not stated (registered criteria)

    Led by West China HospitalChengdu

  397. Enrolling by invitation
    Radiomics-Based AI Model for Predicting Para-Aortic Lymph Node Metastasis in Gastric Cancer Patients
    Phase
    Not given
    Started
    2025-01
    Registry
    NCT06947096

    Age 18 years to 80 years (registered criteria)

    Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang

  398. Enrolling by invitation
    AI-Based Prediction of Lymph Node Metastasis in Gastric Cancer Using Preoperative Multimodal Data
    Phase
    Not given
    Started
    2025-01
    Registry
    NCT06957678

    Age 18 years to 80 years (registered criteria)

    Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang

  399. Enrolling by invitation
    PET Image Exploration of 89Zr-labeled Antibody Fragments Targeting HER2 in Patients With Malignant Tumors
    Phase
    Early phase 1
    Started
    2025-07
    Registry
    NCT07023848

    Age 18 years to 75 years (registered criteria)

    Led by Affiliated Hospital of Jiangnan UniversityWuxi

  400. Enrolling by invitation
    The Exploration of Novel Radionuclide-labeled HER2-targeting Antibodies in the Diagnosis of HER2-positive Malignancies
    Phase
    Early phase 1
    Started
    2025-07
    Registry
    NCT07023861

    Age 15 years to 75 years (registered criteria)

    Led by Affiliated Hospital of Jiangnan UniversityWuxi

  401. Enrolling by invitation
    Explainable Machine Learning for Predicting Early Gastric Cancer
    Phase
    Not given
    Started
    2025-06
    Registry
    NCT07047937

    Age not stated (registered criteria)

    Led by Wenzhou Central HospitalWenzhou

  402. Enrolling by invitation
    An Artificial Intelligence Model for Aiding Claudin18.2 Expression Diagnosis in Gastric Adenocarcinoma
    Phase
    Not given
    Started
    2025-10
    Registry
    NCT07274579

    Age 18 years to Not stated (registered criteria)

    Led by Nanfang Hospital; 1 listed hospital as study siteGuangzhou, Jinan

  403. Enrolling by invitation
    Clinical Efficacy of Pucotenlimab Combined With Lenvatinib and SOX Versus SOX Alone in Patients With HER2-Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
    Phase
    Early phase 1
    Started
    2025-05
    Registry
    NCT07356466

    Age 18 years to 75 years (registered criteria)

    Led by Fujian Medical University Union HospitalFuzhou

  404. Enrolling by invitation
    Safety and Efficacy of Leucine-Restricted Diet in Gastric Cancer
    Phase
    Phase 1
    Started
    2025-10
    Registry
    NCT07488312

    Age 18 years to 70 years (registered criteria)

    Led by Qilu Hospital of Shandong UniversityJinan

  405. Enrolling by invitation
    Laparoscopic Staging for Stage III Gastric Cancer
    Phase
    N/A
    Started
    2025-02
    Registry
    NCT07533825

    Age 18 years to 75 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  406. Enrolling by invitation
    EGPSS for Weight Management in an in Vivo Human Model
    Phase
    N/A
    Started
    2024-07
    Registry
    NCT07186959

    Age 18 years to 70 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  407. Enrolling by invitation
    Screening of Small Non-coding RNAs as an Auxiliary Diagnostic Biomarker for Gastric Cancer
    Phase
    Not given
    Started
    2023-12
    Registry
    NCT06776835

    Age 18 years to 85 years (registered criteria)

    Led by Affiliated Hospital of Nantong UniversityNantong

  408. Enrolling by invitation
    Prolonged Extubation in Gastric Cancer With OSA
    Phase
    Not given
    Started
    2023-01
    Registry
    NCT07362706

    Age 18 years to 85 years (registered criteria)

    Led by Qilu Hospital of Shandong UniversityJinan

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

Before contacting a hospital

The same for every disease, so it is kept on one page. Each hospital page also has an enquiry letter in English and Chinese, and a name card to show staff.

Where these numbers come from

Papers

9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025; a hospital led a paper when its first or last author lists it first. Run the PubMed search

Trials

ClinicalTrials.gov records with a listed hospital as lead sponsor or site, as of 8 Nov 2026. ChiCTR is not included. Search ClinicalTrials.gov

Locations

Locations are shown at city centres. Check the hospital’s website for its address.

Suggest a correctionDownload the data (CSV)Definitions